[go: up one dir, main page]

WO2018151071A1 - Fluorescent labeling method - Google Patents

Fluorescent labeling method Download PDF

Info

Publication number
WO2018151071A1
WO2018151071A1 PCT/JP2018/004802 JP2018004802W WO2018151071A1 WO 2018151071 A1 WO2018151071 A1 WO 2018151071A1 JP 2018004802 W JP2018004802 W JP 2018004802W WO 2018151071 A1 WO2018151071 A1 WO 2018151071A1
Authority
WO
WIPO (PCT)
Prior art keywords
aminocoumarin compound
particles
compound
aminocoumarin
encapsulated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2018/004802
Other languages
French (fr)
Japanese (ja)
Inventor
賢司 西川
健作 高梨
武寿 磯田
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Konica Minolta Inc
Original Assignee
Konica Minolta Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Konica Minolta Inc filed Critical Konica Minolta Inc
Priority to JP2018568515A priority Critical patent/JP7095603B2/en
Publication of WO2018151071A1 publication Critical patent/WO2018151071A1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09B—ORGANIC DYES OR CLOSELY-RELATED COMPOUNDS FOR PRODUCING DYES, e.g. PIGMENTS; MORDANTS; LAKES
    • C09B57/00—Other synthetic dyes of known constitution
    • C09B57/02—Coumarine dyes
    • C—CHEMISTRY; METALLURGY
    • C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09B—ORGANIC DYES OR CLOSELY-RELATED COMPOUNDS FOR PRODUCING DYES, e.g. PIGMENTS; MORDANTS; LAKES
    • C09B67/00—Influencing the physical, e.g. the dyeing or printing properties of dyestuffs without chemical reactions, e.g. by treating with solvents grinding or grinding assistants, coating of pigments or dyes; Process features in the making of dyestuff preparations; Dyestuff preparations of a special physical nature, e.g. tablets, films
    • C09B67/0001—Post-treatment of organic pigments or dyes
    • C09B67/0004—Coated particulate pigments or dyes
    • C09B67/0008—Coated particulate pigments or dyes with organic coatings
    • C09B67/0013—Coated particulate pigments or dyes with organic coatings with polymeric coatings
    • C—CHEMISTRY; METALLURGY
    • C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09B—ORGANIC DYES OR CLOSELY-RELATED COMPOUNDS FOR PRODUCING DYES, e.g. PIGMENTS; MORDANTS; LAKES
    • C09B67/00—Influencing the physical, e.g. the dyeing or printing properties of dyestuffs without chemical reactions, e.g. by treating with solvents grinding or grinding assistants, coating of pigments or dyes; Process features in the making of dyestuff preparations; Dyestuff preparations of a special physical nature, e.g. tablets, films
    • C09B67/0071—Process features in the making of dyestuff preparations; Dehydrating agents; Dispersing agents; Dustfree compositions
    • C09B67/0084—Dispersions of dyes
    • C09B67/0085—Non common dispersing agents
    • C09B67/009—Non common dispersing agents polymeric dispersing agent
    • C—CHEMISTRY; METALLURGY
    • C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09B—ORGANIC DYES OR CLOSELY-RELATED COMPOUNDS FOR PRODUCING DYES, e.g. PIGMENTS; MORDANTS; LAKES
    • C09B67/00—Influencing the physical, e.g. the dyeing or printing properties of dyestuffs without chemical reactions, e.g. by treating with solvents grinding or grinding assistants, coating of pigments or dyes; Process features in the making of dyestuff preparations; Dyestuff preparations of a special physical nature, e.g. tablets, films
    • C09B67/0097—Dye preparations of special physical nature; Tablets, films, extrusion, microcapsules, sheets, pads, bags with dyes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531—Production of immunochemical test materials
    • G01N33/532—Production of labelled immunochemicals
    • G01N33/533—Production of labelled immunochemicals with fluorescent label

Definitions

  • the present invention relates to an immunostaining method and a fluorescent labeling method such as FISH, in which an aminocoumarin compound is used as a dye and labeling is performed with aminocoumarin compound-encapsulating resin particles encapsulating the aminocoumarin compound.
  • an antigen is fluorescently labeled by specifically binding a fluorescently labeled antibody to an in vivo molecule (antigen) whose expression level is increased or decreased depending on the presence or absence of the disease, and the amount of fluorescent signal is used to determine the disease. Quantifying the amount of antigen associated with.
  • an antibody is directly or indirectly bound to a nanoparticle encapsulating a fluorescent dye and bound to an antigen. Yes.
  • the fluorescent dye a dye that emits light in each of the green region, the red region, the orange region, and the far infrared region is used.
  • Examples of the dye that emits light in the green region include Pyrromethene 556 described in Patent Document 2.
  • fluorescent labeling is performed using nanoparticles containing Pyrromethene 556, the green bright spot is unclear, and in the case of multiple labels, leakage into other color regions is large, and effective observation cannot be performed. There was a problem.
  • the present invention seeks to solve the problems associated with the prior art as described above, and has a clear green luminescent spot, and in the case of multiple labels, a fluorescent labeling method with little leakage into other color regions.
  • the purpose is to provide.
  • the present inventors have used an aminocoumarin compound having a specific structure as a green pigment, and by labeling with an aminocoumarin compound-encapsulated particle encapsulating this aminocoumarin compound.
  • the present inventors have found that the above problems can be solved and have completed the present invention.
  • labeling is performed using aminocoumarin compound-encapsulated particles in which an aminocoumarin compound having a structure represented by the following formula (1) or (2) or a salt thereof is encapsulated in base particles.
  • This is a fluorescent labeling method.
  • each R independently represents a hydrogen atom or a methyl group
  • Q represents a sulfur atom, an oxygen atom or N—R 1
  • R 1 represents a hydrogen atom or a methyl group.
  • A independently represents a hydrogen atom or a methyl group
  • Q represents a sulfur atom, an oxygen atom or N—R 1
  • R 1 represents a hydrogen atom or a methyl group.
  • the average particle size of the aminocoumarin compound-containing particles is preferably 80 to 200 nm.
  • the fluorescent labeling method can perform multiple labeling including labeling using the aminocoumarin compound-encapsulated particles. Examples of the fluorescent labeling method include immunostaining and FISH.
  • Preferable embodiments of the immunostaining method include PDL1, CTLA4, CD8, CD30, CD48, CD59, IDO, TDO, CSF-1R, HDAC, CXCR4, FLT-3, TIGIT, INF- ⁇ , INF- ⁇ , INF- ⁇ , INF- ⁇ , INF- ⁇ , INF- ⁇ CSF, EPO, EGF, FGF, PDGF, HGF, TGF, CD3, CD4, CD25, CD28, CD80, CD86, CD160, CD57, OX40 (CD134) ), OX40L (CD252), ICOS (CD278), ICOSL (CD275), CD155, CD226, CD112, CD27, CD70, 4-1BB (CD137), 4-1BBL (CD137L), GITR (CD357), GITRL, BTLA ( CD272), HVEM (CD270), TIM-3, Galle Cutin-9 (Galectin-9), LAG-3 (CD223), B7-H3
  • a green bright spot is clear, and in the case of multiple labels, leakage into other color areas, for example, a red area is small, and a green bright spot and a red bright spot are detected. A good balance with the points is obtained.
  • the fluorescent labeling method of the present invention is a fluorescent label for labeling using an aminocoumarin compound-encapsulated particle in which an aminocoumarin compound having a structure represented by the following formula (1) or (2) or a salt thereof is encapsulated in a base particle. Is the law.
  • R's each independently represent a hydrogen atom or a methyl group.
  • six A's each independently represent a hydrogen atom or a methyl group.
  • Q represents a sulfur atom, an oxygen atom or N—R 1 .
  • R 1 represents a hydrogen atom or a methyl group.
  • the aminocoumarin compound of the present invention has a benzothiazole structure when Q in formula (1) or (2) is a sulfur atom, and has a benzoxazole structure when Q is an oxygen atom, and N—R 1 In some cases, it will have a benzimidazole structure.
  • the sulfonic acid group SO 3 H contained in the formulas (1) and (2) is any carbon atom among the four carbon atoms that can be bonded to the benzene ring contained in the benzothiazole structure, benzoxazole structure or benzimidazole structure. May be bonded to.
  • the aminocoumarin compound having the structure represented by the formula (1) and the aminocoumarin compound having the structure represented by the formula (2) have a sulfonated benzothiazole residue, benzoxazole residue or benzimidazole residue. Common in that it has an aminocoumarin structure.
  • the nitrogen atom bonded to the coumarin structure forms two 6-membered rings together with the four carbon atoms of the benzene ring contained in the coumarin structure, That is, the structure is different from a known sulfonated coumarin compound in that the amino group of aminocoumarin has a julolidine structure.
  • the aminocoumarin compound having the structure represented by the formula (1) has an excitation wavelength longer than that of a known sulfonated coumarin compound, and a wavelength giving a maximum excitation intensity is 475 nm or more, for example, at 475 to 510 nm. is there.
  • the aminocoumarin compound of the present invention also has a longer emission wavelength than known sulfonated coumarin compounds, and the wavelength that gives the maximum emission intensity is 510 nm or more, for example, 510 to 540 nm.
  • the aminocoumarin compound represented by the formula (1) has a feature that the emission intensity is higher than that of an aminocoumarin compound formed by substituting the sulfone group of the aminocoumarin compound with a hydrogen atom.
  • An aminocoumarin compound having a structure represented by the formula (1) can be produced, for example, by a method of sulfonating a coumarin compound having a structure represented by the following formula (3). Specifically, it can be produced by adding 1 ml of fuming sulfuric acid to 0.1 g of the coumarin compound represented by the formula (3) and reacting at 0 to 140 ° C. for 1 to 8 hours.
  • An aminocoumarin compound having a structure represented by the formula (2) can be produced, for example, by a method of sulfonating a coumarin compound having a structure represented by the following formula (4). Specifically, it can be produced by adding 1 ml of fuming sulfuric acid to 0.1 g of the coumarin compound represented by formula (4) and reacting at 0 to 140 ° C. for 1 to 8 hours.
  • the aminocoumarin compound-encapsulated particles have an aminocoumarin compound having a structure represented by formula (1) or formula (2) and base particles encapsulating the aminocoumarin compound.
  • the base particles encapsulating the aminocoumarin compound are organic particles or inorganic particles, and are not particularly limited as long as the aminocoumarin compound can be encapsulated.
  • the organic particles are preferably thermosetting resins. Since the thermosetting resin has a three-dimensional network structure, the aminocoumarin compound encapsulated in the thermosetting resin is not easily detached from the resin particles, and is suitable for fluorescent labeling such as immunostaining.
  • the thermosetting resin include melamine resin, urea resin, aniline resin, guanamine resin, phenol resin, xylene resin, and furan resin. Among these, amino resins such as melamine resin and urea resin are particularly preferable because they can more effectively suppress the release of the pigment from the resin particles.
  • the inorganic particles include silica particles and glass particles.
  • the amount of the aminocoumarin compound encapsulated in the base particle is not particularly limited, and may be an amount that can ensure a detectable luminance when the aminocoumarin compound-encapsulated particle is used for a fluorescent label such as immunostaining.
  • the average particle diameter of the aminocoumarin compound-encapsulated particles is not particularly limited, but when used for fluorescent labeling such as immunostaining, it is usually 20 to 500 nm, preferably 80 to 200 nm. If the average particle size of the aminocoumarin compound-containing particles exceeds 200 nm, there may be a problem with labeling properties, and if it is less than 80 nm, there may be problems with visibility.
  • the average particle size is calculated as an average value obtained by measuring the particle size of 1000 aminocoumarin compound-encapsulated particles by SEM observation.
  • the production method of the aminocoumarin compound-encapsulated particles is not particularly limited, and a known method can be adopted. In general, a method of forming a matrix such as a resin or silica in the presence of an aminocoumarin compound and encapsulating the aminocoumarin compound in the matrix particles can be used.
  • an aminocoumarin compound is added while (co) polymerizing the (co) monomer for synthesizing the base particle by emulsion polymerization, and the (co) polymer is added.
  • a method of incorporating an aminocoumarin compound into the inside or the surface of can be used.
  • the base particles are inorganic particles such as silica
  • the method for synthesizing FITC-encapsulated silica nanoparticles described in Langmuir Vol. 8, Vol. 9, page 2921 (1992) can be referred to.
  • Aminocoumarin compound-encapsulated silica nanoparticles can be synthesized by using an aminocoumarin compound instead of FITC.
  • the wavelength that gives the maximum excitation intensity is preferably 475 to 510 nm, and the wavelength that gives the maximum emission intensity is preferably 510 to 540 nm.
  • the aminocoumarin compound-encapsulating resin particle produced by encapsulating the aminocoumarin compound represented by the formula (1) in the resin is obtained by replacing the sulfone group of the aminocoumarin compound with a hydrogen atom.
  • the emission intensity tends to be strong. This is because the aminocoumarin compound represented by the formula (1) is more easily included in the resin than the aminocoumarin compound formed by replacing the sulfone group of the aminocoumarin compound with a hydrogen atom. It is presumed that it is taken in.
  • fluorescent labeling method of the present invention labeling is performed using the aminocoumarin compound-encapsulated particles.
  • the fluorescent labeling method include immunostaining and FISH.
  • the specific operation method of immunostaining and FISH is not particularly limited, and a known method can be used.
  • the aminocoumarin compound-encapsulated particles may be used as the dye particles.
  • the aminocoumarin compound-encapsulated particles can be used to stain not only HER2 and Ki67 but also proteins to be stained such as PDL1, CTLA4, CD8, CD30, CD48, and CD59.
  • the fluorescent labeling method of the present invention may be a multiple label including a label using the aminocoumarin compound-encapsulated particles. That is, multiple labeling can be performed on two or more labeling targets using different dyes, and at least one of the staining targets can be labeled using the aminocoumarin compound-encapsulated particles. For example, for a plurality of labeling targets, some of the labeling targets are labeled using the aminocoumarin compound-containing particles, and particles containing a dye that emits light other than green are used for other labeling targets. Thus, a plurality of objects to be labeled can be separately labeled with green and a color other than green.
  • multiple staining is performed on at least two proteins to be stained selected from PDL1, CTLA4, CD8, CD30, CD48 and CD59 using different dyes, and at least one of the proteins to be stained is selected.
  • PDL1 can be stained green with aminocoumarin compound-encapsulated particles
  • CTLA4 can be stained with red
  • PDL1 and CTLA4 can be labeled with different colors.
  • the aminocoumarin compound has a light emitting region close to a red region as compared with a coumarin compound other than the aminocoumarin compound.
  • a coumarin other than the aminocoumarin compound is used. The effect that the leakage into the red region is rather smaller than that of the pigment particles containing the compound is obtained.
  • the recovered precipitate was dispersed with ethanol, the dispersion was centrifuged, and the supernatant was removed to obtain an aminocoumarin compound I represented by the following formula (I) as a precipitate.
  • the yield of aminocoumarin compound I was 80%.
  • the obtained powder was added to pure water, then neutralized with an aqueous NaOH solution to dissolve the precipitate, and the pH of the solution was adjusted to 7-8.
  • This solution was dried with a freeze dryer to obtain Na salt of aminocoumarin compound I. It was confirmed that the aminocoumarin compound I dissolves quickly in water by using Na salt, whereas the sulfonic acid form has poor solubility in water.
  • the resulting organoalkoxysilane compound solution (0.3 mL) was mixed with 99% ethanol (24 mL), tetraethoxysilane (TEOS) (0.3 mL), ultrapure water (0.75 mL), and 28% by mass of ammonia water (0.75 mL) at 25 ° C. Mixed for hours.
  • TEOS tetraethoxysilane
  • the mixed solution prepared in the above step was centrifuged at 10,000 G for 20 minutes, and the supernatant was removed. To this precipitate, ethanol was added to disperse the precipitate, and rinsing was performed again by centrifugation. Further, similar rinsing was repeated twice to obtain aminocoumarin compound-encapsulated particles I. When 1000 particles of the obtained particles were observed with an SEM and the average particle size was measured, the average particle size was 60 nm.
  • Aminocoumarin compound-encapsulated particles VI were obtained in the same manner as in Production Example 3 except that aminocoumarin compound II was used instead of aminocoumarin compound I. When 1000 particles of the obtained particles were observed with an SEM and the average particle size was measured, the average particle size was 150 nm.
  • the solution was heated to 70 ° C. while stirring on a hot stirrer, and then 0.65 g of melamine resin raw material Nicalak MX-035 (manufactured by Nippon Carbide Industries Co., Ltd.) was added to the solution.
  • melamine resin raw material Nicalak MX-035 manufactured by Nippon Carbide Industries Co., Ltd.
  • To this solution was added 1000 ⁇ L of a 10% aqueous solution of dodecylbenzenesulfonic acid (manufactured by Kanto Chemical Co., Ltd.) as a reaction initiator, and the mixture was heated and stirred at 70 ° C. for 50 minutes, then heated to 90 ° C. and stirred for 20 minutes.
  • aminocoumarin compound-encapsulated particles VII were obtained.
  • the obtained dispersion liquid of aminocoumarin compound-encapsulating resin particles VII was washed with pure water to remove impurities such as excess resin material and aminocoumarin compound. Specifically, the mixture was centrifuged at 20000 G for 15 minutes in a centrifuge (Kubota Micro Cooling Centrifuge 3740), and after removing the supernatant, ultrapure water was added and ultrasonically irradiated to redisperse. Centrifugation, supernatant removal, and washing by redispersion in ultrapure water were repeated 5 times. When 1000 particles of aminocoumarin compound-encapsulated particles VII were observed with SEM and the average particle size was measured, the average particle size was 150 nm.
  • Dye-containing particles i were obtained in the same manner as in Production Example 1 except that Pyrromethene 556, which is a green pigment, was used instead of aminocoumarin compound I. When 1000 particles of the obtained particles were observed with an SEM and the average particle size was measured, the average particle size was 150 nm.
  • Dye-encapsulated particles ii were obtained in the same manner as in Production Example 7 except that Pyrromethene 556, which is a green pigment, was used instead of aminocoumarin compound I. When 1000 particles of the obtained particles were observed with an SEM and the average particle size was measured, the average particle size was 150 nm.
  • Example 1 Immunostaining was performed by the following method. (Modification of dye-encapsulated particles with streptavidin) Aminocoumarin compound-encapsulated particles I were adjusted to 3 nM using PBS (phosphate buffered saline) containing 2 mM of EDTA (ethylenediaminetetraacetic acid), and SM (PEG) was added to this solution to a final concentration of 10 mM. ) 12 (manufactured by Thermo Scientific, succinimidyl-[(N-maleimidopropionamid) -dodecaneethyleneglycol] ester) was mixed and reacted at 5 ° C. for 1 hour.
  • the mixture was centrifuged at 10,000 G for 20 minutes, the supernatant was removed, PBS containing 2 mM of EDTA was added, the precipitate was dispersed, and the mixture was centrifuged again. By performing washing by the same procedure three times, aminocoumarin compound-encapsulated particles I having a maleimide group at the end were obtained.
  • streptavidin solution was desalted with a gel filtration column (Zaba Spin Desaling Columns: Funakoshi) to obtain streptavidin capable of binding to the silica particles.
  • This total amount of streptavidin (containing 0.04 mg) was mixed with 740 ⁇ L of the silica-based particles adjusted to 0.67 nM using PBS containing 2 mM of EDTA, and reacted at room temperature for 1 hour.
  • the reaction solution was purified by subjecting it to a desalting column “Zeba Desalt Spin Spin Columns” (Thermo Scientific Cat. # 89882). Absorption at a wavelength of 300 nm of the desalted reaction solution was measured with a spectrophotometer (Hitachi “F-7000”) to calculate the amount of protein contained in the reaction solution.
  • the reaction solution was adjusted to 250 ⁇ g / mL with a 50 mM Tris solution, and this solution was used as a biotinylated secondary antibody solution.
  • Specimen processing step (1-1) Deparaffinization processing step HER2 (3+) and HER2 (-) tissue array slides ("CB-A712 series” manufactured by Cosmo Bio) are used as tissue sections for staining. It was. The tissue array slide was deparaffinized.
  • Activation treatment step Washing was performed by replacing the deparaffinized tissue array slide with water.
  • the washed tissue array slide was autoclaved at 121 ° C. for 15 minutes in 10 mM citrate buffer (pH 6.0) to activate the antigen.
  • the tissue array slide after the activation treatment was washed with PBS, and the washed tissue array slide was subjected to blocking treatment with PBS containing 1% BSA for 1 hour.
  • tissue sections that had undergone the immunostaining step and the morphological observation staining step were immersed in pure ethanol for 5 minutes four times, and washed and dehydrated. Subsequently, the operation of immersing in xylene for 5 minutes was carried out 4 times to perform clearing. Finally, a tissue section slide of a sample for observation was prepared by enclosing a tissue section using an encapsulant (“Enteran New” manufactured by Merck).
  • the tissue section after the immobilization treatment step was irradiated with predetermined excitation light to emit fluorescence.
  • the tissue sections in this state were observed and imaged with a fluorescence microscope (OLYMPUS "BX-53") and a digital camera for microscope (OLYMPUS "DP73").
  • the excitation light was set to 575 to 600 nm by passing through an optical filter.
  • the range of the wavelength (nm) of fluorescence to be observed was also set to 612 to 692 nm by passing through an optical filter.
  • the conditions of the excitation wavelength during microscopic observation and image acquisition were such that the irradiation energy near the center of the field of view was 900 W / cm 2 for excitation at 580 nm.
  • the exposure time at the time of image acquisition was arbitrarily set so as not to saturate the brightness of the image (for example, set to 4000 ⁇ sec) and imaged.
  • the number of bright spots of the HER2 (3+) tissue was an average value of 1000 cells measured by the ImageJ FindMaxims method based on an image captured at 400 times.
  • the number S of bright spots on the cell membrane in the field of view and the number N of bright spots outside the field in the field of view were measured, and S / N was calculated. S / N is shown in Table 1.
  • Examples 2 to 5, 7, 8 (Modification of dye-encapsulated particles with streptavidin)
  • streptavidin-linked amino acid was prepared in the same manner as in Example 1 except that aminocoumarin compound-encapsulated particles II to VI and VIII were used instead of aminocoumarin compound-encapsulated particle I, respectively.
  • Coumarin compound-encapsulated particles II to VI and VIII were obtained, respectively.
  • Examples 2 to 5, 7, and 8 were the same as Example 1 except that streptavidin-conjugated aminocoumarin compound-encapsulated particles I were used instead of streptavidin-conjugated aminocoumarin compound-encapsulated particles I, respectively.
  • S / N was calculated by the method. S / N is shown in Table 1.
  • Example 6 Modification of dye-encapsulated particles with streptavidin
  • Streptavidin-linked aminocoumarin compound-encapsulated particles III were obtained in the same manner as in Example 1 except that aminocoumarin compound-encapsulated particles III were used instead of aminocoumarin compound-encapsulated particles I.
  • a biotinylated secondary antibody solution was obtained in the same manner as in Example 1.
  • tissue array slide of PDL1 was used as a tissue section for staining.
  • the tissue array slide was deparaffinized.
  • Activation treatment step Washing was performed by replacing the deparaffinized tissue array slide with water.
  • the washed tissue array slide was autoclaved in a 10 mM citrate buffer (pH 6.0) at 121 ° C. for 15 minutes to activate the antigen.
  • the tissue array slide after the activation treatment was washed with PBS, and the washed tissue array slide was subjected to blocking treatment with PBS containing 1% BSA for 1 hour.
  • tissue sections that had undergone the immunostaining step and the morphological observation staining step were immersed in pure ethanol for 5 minutes four times, and washed and dehydrated. Subsequently, the operation of immersing in xylene for 5 minutes was carried out 4 times to perform clearing. Finally, a tissue section slide of a sample for observation was prepared by enclosing a tissue section using an encapsulant (“Enteran New” manufactured by Merck).
  • Example 9 (Modification of dye-encapsulated particles with streptavidin) Streptavidin-linked aminocoumarin compound-encapsulated particles VIII were obtained in the same manner as in Example 1 except that aminocoumarin compound-encapsulated particles VIII were used instead of aminocoumarin compound-encapsulated particles I.
  • Step (1) The tissue specimen was immersed in a container containing xylene for 15 minutes. The xylene was changed twice during the process.
  • Step (2) The tissue specimen was immersed in a container containing ethanol for 10 minutes. The ethanol was changed twice during the process.
  • Step (3) The tissue specimen was immersed in a container containing water for 10 minutes.
  • Step (4) The tissue specimen was immersed in a 10 mM citrate buffer (pH 6.0).
  • Process (5) The autoclave process was performed for 5 minutes at 121 degreeC.
  • Step (6) The tissue specimen after the autoclave treatment was immersed in a container containing PBS for 15 minutes. The PBS was changed three times during the process.
  • Step (7) PBS containing 1% BSA was placed on the tissue specimen and allowed to stand for 1 hour.
  • Step (10) Anti-Ki67 antibody-binding dye-encapsulated particles adjusted to 0.1 nM with PBS containing 1% BSA were placed on a tissue specimen and allowed to stand overnight to label Ki67.
  • Step (11) The labeled tissue specimen was immersed in a container containing PBS for 30 minutes.
  • Step (12) The tissue specimen was fixed with a 4% neutral paraformaldehyde solution for 10 minutes, and then stained with HE.
  • Step (13) After dropping Aquack made by Merck, a cover glass was placed and a tissue specimen was enclosed.
  • the tissue specimen after immunostaining was placed on the stage, and each time the filter set was switched while switching between two types of filter sets for green and red, the number of fluorescent luminescent spots in the fluorescence image of the tissue specimen was measured. The results are shown in Table 3.
  • Examples 11 and 12 In Examples 11 and 12, multiple immunostaining was performed in the same manner as in Example 10 except that aminocoumarin compound-encapsulated particles IX and aminocoumarin compound-encapsulated particles VIII were used instead of aminocoumarin compound-encapsulated resin particles VII, respectively. went. The results are shown in Table 3.
  • Example 13 Multiple immunostaining of green and red was performed by the following method.
  • Aminocoumarin compound-encapsulated particle VIII is introduced with maleimide using NHS-PEG (polyethylene glycol) -maleimide reagent at the end, and thiolated anti-CTLA4 antibody is bound thereto to produce an anti-CTLA4 antibody-bound aminocoumarin compound-encapsulated particle did.
  • maleimide was introduced into the end of the dye-encapsulated particle iii, and a thiolated anti-PDL1 antibody was bound thereto to produce an anti-CTLA4 antibody-bound dye-encapsulated particle.
  • Step (1) The tissue specimen was immersed in a container containing xylene for 15 minutes. The xylene was changed twice during the process.
  • Step (2) The tissue specimen was immersed in a container containing ethanol for 10 minutes. The ethanol was changed twice during the process.
  • Step (3) The tissue specimen was immersed in a container containing water for 10 minutes.
  • Step (4) The tissue specimen was immersed in a 10 mM citrate buffer (pH 6.0).
  • Process (5) The autoclave process was performed for 5 minutes at 121 degreeC.
  • Step (6) The tissue specimen after the autoclave treatment was immersed in a container containing PBS for 15 minutes. The PBS was changed three times during the process.
  • Step (7) PBS containing 1% BSA was placed on the tissue specimen and allowed to stand for 1 hour.
  • Step (9) The labeled tissue specimen was immersed in a container containing PBS for 15 minutes.
  • Step (10) Anti-CTLA4 antibody-binding dye-encapsulated particles adjusted to 0.1 nM with PBS containing 1% BSA were placed on a tissue specimen and allowed to stand overnight to label PDL1.
  • Step (11) The labeled tissue specimen was immersed in a container containing PBS for 30 minutes.
  • Step (12) The tissue specimen was fixed with a 4% neutral paraformaldehyde solution for 10 minutes, and then stained with HE.
  • Step (13) After dropping Aquack made by Merck, a cover glass was placed and a tissue specimen was enclosed. (Microscopic observation) Microscopic observation was performed in the same manner as in Example 10. The results are shown in Table 4.
  • Example 14 Multiple immunostaining of green and red was performed by the following method.
  • Maleimide was introduced into the end of the aminocoumarin compound-encapsulated particles VIII using NHS-PEG (polyethylene glycol) -maleimide reagent, and thiolated anti-CD8 antibody ("DCD” anti-CD8 mouse monoclonal antibody (C8 / 144B )]) was bound to produce anti-CD8 antibody-bound aminocoumarin compound-encapsulated particles.
  • Step (1) The tissue specimen was immersed in a container containing xylene for 15 minutes. The xylene was changed twice during the process.
  • Step (2) The tissue specimen was immersed in a container containing ethanol for 10 minutes. The ethanol was changed twice during the process.
  • Step (3) The tissue specimen was immersed in a container containing water for 10 minutes.
  • Step (4) The tissue specimen was immersed in a 10 mM citrate buffer (pH 6.0).
  • Process (5) The autoclave process was performed for 5 minutes at 121 degreeC.
  • Step (6) The tissue specimen after the autoclave treatment was immersed in a container containing PBS for 15 minutes. The PBS was changed three times during the process.
  • Step (7) PBS containing 1% BSA was placed on the tissue specimen and allowed to stand for 1 hour.
  • Step (10) Anti-PDL1 antibody-binding dye-encapsulated particles adjusted to 0.1 nM with PBS containing 1% BSA were placed on a tissue specimen and allowed to stand overnight to label PDL1.
  • Step (11) The labeled tissue specimen was immersed in a container containing PBS for 30 minutes.
  • Step (12) The tissue specimen was fixed with a 4% neutral paraformaldehyde solution for 10 minutes, and then stained with HE.
  • Step (13) After dropping Aquack made by Merck, a cover glass was placed and a tissue specimen was enclosed. (Microscopic observation) Microscopic observation was performed in the same manner as in Example 10. The results are shown in Table 4.
  • Anti-CD30 antibody manufactured by Dako, “Anti-CD30 mouse monoclonal antibody (BerH2) obtained by introducing maleimide into the end of aminocoumarin compound-encapsulated particles VIII using NHS-PEG (polyethylene glycol) -maleimide reagent and thiolating it. Were bound to produce anti-CD30 antibody-bound aminocoumarin compound-encapsulated particles.
  • Step (1) The tissue specimen was immersed in a container containing xylene for 15 minutes. The xylene was changed twice during the process.
  • Step (2) The tissue specimen was immersed in a container containing ethanol for 10 minutes. The ethanol was changed twice during the process.
  • Step (3) The tissue specimen was immersed in a container containing water for 10 minutes.
  • Step (4) The tissue specimen was immersed in a 10 mM citrate buffer (pH 6.0).
  • Process (5) The autoclave process was performed for 5 minutes at 121 degreeC.
  • Step (6) The tissue specimen after the autoclave treatment was immersed in a container containing PBS for 15 minutes. The PBS was changed three times during the process.
  • Step (7) PBS containing 1% BSA was placed on the tissue specimen and allowed to stand for 1 hour.
  • Step (10) Anti-PDL1 antibody-binding dye-encapsulated particles adjusted to 0.1 nM with PBS containing 1% BSA were placed on a tissue specimen and allowed to stand overnight to label PDL1.
  • Step (11) The labeled tissue specimen was immersed in a container containing PBS for 30 minutes.
  • Step (12) The tissue specimen was fixed with a 4% neutral paraformaldehyde solution for 10 minutes, and then stained with HE.
  • Step (13) After dropping Aquack made by Merck, a cover glass was placed and a tissue specimen was enclosed. (Microscopic observation) Microscopic observation was performed in the same manner as in Example 10. The results are shown in Table 4.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Dispersion Chemistry (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

The present invention is a fluorescent labeling method for a labeling using particles containing an aminocoumarin compound, which are obtained by including an aminocoumarin compound or salt thereof having the structure represented by formula (1) or (2) in matrix particles. In formula (1), R each independently represent a hydrogen atom or a methyl group, Q represents a sulfur atom, an oxygen atom, or N-R1, and R1 represents a hydrogen atom or a methyl group. In formula (2), A each independently represent a hydrogen atom or a methyl group, Q represents a sulfur atom, an oxygen atom, or N-R1, and R1 represents a hydrogen atom or a methyl group. According to this fluorescent labeling method, green luminescent spots are evident, and in cases of simultaneous multi-color dyeing, there is little leakage into other color regions, e.g., red regions, and it is possible to attain an excellent balance between green luminescent spots and red luminescent spots.

Description

蛍光標識法Fluorescent labeling method

　本発明は、色素としてアミノクマリン化合物を用い、このアミノクマリン化合物が内包されたアミノクマリン化合物内包樹脂粒子により標識を行う、免疫染色法およびＦＩＳＨ等の蛍光標識法に関する。 The present invention relates to an immunostaining method and a fluorescent labeling method such as FISH, in which an aminocoumarin compound is used as a dye and labeling is performed with aminocoumarin compound-encapsulating resin particles encapsulating the aminocoumarin compound.

　現在、免疫染色法およびＦＩＳＨ等の蛍光標識法が広く利用されている。
　たとえば、医療においては、被験者が対象疾患に罹患しているか否かを判断するためのデータを提供するために、被験者の組織切片等について免疫染色が広く行われている。この免疫染色では、例えば、前記罹患の有無によって発現量が増減する生体内の分子（抗原）に、蛍光標識した抗体を特異的に結合させることにより抗原を蛍光標識し、蛍光シグナルの量から疾患に関連する抗原の量を定量することが行われる。蛍光標識した抗体を抗原に結合させる技術として、蛍光色素を粒子に内包させたナノ粒子に抗体を直接的または間接的に結合させ、これを抗原に結合させる技術がたとえば特許文献１に開示されている。 Currently, immunostaining methods and fluorescent labeling methods such as FISH are widely used.
For example, in medical practice, immunostaining is widely performed on tissue sections and the like of subjects in order to provide data for determining whether or not a subject suffers from a target disease. In this immunostaining, for example, an antigen is fluorescently labeled by specifically binding a fluorescently labeled antibody to an in vivo molecule (antigen) whose expression level is increased or decreased depending on the presence or absence of the disease, and the amount of fluorescent signal is used to determine the disease. Quantifying the amount of antigen associated with. As a technique for binding a fluorescently labeled antibody to an antigen, for example, Patent Document 1 discloses a technique in which an antibody is directly or indirectly bound to a nanoparticle encapsulating a fluorescent dye and bound to an antigen. Yes.

　蛍光色素としては、緑色領域、赤色領域、オレンジ色領域および遠赤外線領域の各領域において発光を呈する色素がそれぞれ用いられている。異なる領域において発光する２種以上の色素を用いて、２つ以上の領域において同時に標識を行う多重標識は、きわめて有効な標識手段であって、その技術の発展が期待されている。 As the fluorescent dye, a dye that emits light in each of the green region, the red region, the orange region, and the far infrared region is used. Multiple labeling, in which two or more dyes that emit light in different regions and simultaneously labeling in two or more regions, is an extremely effective labeling means, and development of the technology is expected.

　緑色領域で発光する色素としては、たとえば特許文献２に記載されたＰｙｒｒｏｍｅｔｈｅｎｅ５５６が挙げられる。
　しかし、Ｐｙｒｒｏｍｅｔｈｅｎｅ５５６を内包したナノ粒子を用いて蛍光標識を行うと、緑色の輝点が不明瞭であり、また多重標識の場合、他の色領域への漏れ込みが大きく、効果的な観察ができないという問題があった。 Examples of the dye that emits light in the green region include Pyrromethene 556 described in Patent Document 2.
However, when fluorescent labeling is performed using nanoparticles containing Pyrromethene 556, the green bright spot is unclear, and in the case of multiple labels, leakage into other color regions is large, and effective observation cannot be performed. There was a problem.

ＷＯ２０１５／１５９７７６WO2015 / 159976 ＷＯ２０１２／１３３９２０WO2012 / 133920

　本発明は、上記のような従来技術に伴う問題を解決しようとするものであって、緑色の輝点が明瞭であり、多重標識の場合、他の色領域への漏れ込みが小さい蛍光標識法を提供することを目的とする。 The present invention seeks to solve the problems associated with the prior art as described above, and has a clear green luminescent spot, and in the case of multiple labels, a fluorescent labeling method with little leakage into other color regions. The purpose is to provide.

　本発明者らは、上記問題点を解決すべく鋭意研究した結果、緑色色素として特定構造を有するアミノクマリン化合物を用い、このアミノクマリン化合物が内包されたアミノクマリン化合物内包粒子により標識を行うことにより上記の課題を解決できることを見出し、本発明を完成するに至った。 As a result of diligent research to solve the above problems, the present inventors have used an aminocoumarin compound having a specific structure as a green pigment, and by labeling with an aminocoumarin compound-encapsulated particle encapsulating this aminocoumarin compound. The present inventors have found that the above problems can be solved and have completed the present invention.

　すなわち、本発明の蛍光標識法は、下記式（１）または（２）で示される構造を有するアミノクマリン化合物またはその塩を母体粒子に内包してなるアミノクマリン化合物内包粒子を用いて標識を行う蛍光標識法である。 That is, in the fluorescent labeling method of the present invention, labeling is performed using aminocoumarin compound-encapsulated particles in which an aminocoumarin compound having a structure represented by the following formula (1) or (2) or a salt thereof is encapsulated in base particles. This is a fluorescent labeling method.

Figure JPOXMLDOC01-appb-C000003
（式（１）中、Ｒは、それぞれ独立に水素原子またはメチル基を表わし、Ｑはイオウ原子、酸素原子またはＮ－Ｒ1を表わし、Ｒ1は水素原子またはメチル基を表わす。）
Figure JPOXMLDOC01-appb-C000003
 (In formula (1), each R independently represents a hydrogen atom or a methyl group, Q represents a sulfur atom, an oxygen atom or N—R 1 , and R 1 represents a hydrogen atom or a methyl group.)

Figure JPOXMLDOC01-appb-C000004
（式（２）中、Ａは、それぞれ独立に水素原子またはメチル基を表わし、Ｑはイオウ原子、酸素原子またはＮ－Ｒ1を表わし、Ｒ1は水素原子またはメチル基を表わす。）
Figure JPOXMLDOC01-appb-C000004
 (In the formula (2), A independently represents a hydrogen atom or a methyl group, Q represents a sulfur atom, an oxygen atom or N—R 1 , and R 1 represents a hydrogen atom or a methyl group.)

　前記蛍光標識法において、前記アミノクマリン化合物内包粒子の平均粒径が８０～２００ｎｍであることが好ましい。
　前記蛍光標識法は、前記アミノクマリン化合物内包粒子を用いた標識を含む多重標識を行うことができる。
　前記蛍光標識法は、たとえば免疫染色法およびＦＩＳＨである。 In the fluorescent labeling method, the average particle size of the aminocoumarin compound-containing particles is preferably 80 to 200 nm.
The fluorescent labeling method can perform multiple labeling including labeling using the aminocoumarin compound-encapsulated particles.
Examples of the fluorescent labeling method include immunostaining and FISH.

　前記免疫染色法の好適な態様として、ＰＤＬ１、ＣＴＬＡ４、ＣＤ８、ＣＤ３０、ＣＤ４８、ＣＤ５９、ＩＤＯ、 ＴＤＯ、ＣＳＦ－１Ｒ、ＨＤＡＣ、ＣＸＣＲ４、ＦＬＴ－３、ＴＩＧＩＴ、ＩＮＦ-α、INF-β、INF-ω、INF-ε、INF-κ、INF-γ、INF-λ ＣＳＦ、ＥＰＯ、ＥＧＦ、ＦＧＦ、ＰＤＧＦ、ＨＧＦ、ＴＧＦ、ＣＤ３、ＣＤ４、ＣＤ２５、ＣＤ２８、ＣＤ８０、ＣＤ８６、ＣＤ１６０、ＣＤ５７、ＯＸ４０（ＣＤ１３４）、ＯＸ４０Ｌ（ＣＤ２５２）、ＩＣＯＳ（ＣＤ２７８）、ＩＣＯＳＬ（ＣＤ２７５）、ＣＤ１５５、ＣＤ２２６、ＣＤ１１２、ＣＤ２７、ＣＤ７０、４－１ＢＢ（ＣＤ１３７）、４－１ＢＢＬ（ＣＤ１３７Ｌ）、ＧＩＴＲ（ＣＤ３５７）、ＧＩＴＲＬ、ＢＴＬＡ（ＣＤ２７２）、ＨＶＥＭ（ＣＤ２７０）、ＴＩＭ－３、ガレクチン－９（Ｇａｌｅｃｔｉｎ－９）、ＬＡＧ－３（ＣＤ２２３）、Ｂ７－Ｈ３（ＣＤ２７６）、Ｂ７－Ｈ４、Ｂ７－Ｈ５、ＣＤ４０、ＣＤ４０Ｌ、ＰＤ－１、ＰＤ－Ｌ２、２Ｂ４（ＣＤ２４４）、ＫＬＲＧ－１、Ｅ－Ｃａｄｈｅｒｉｎ、Ｎ－Ｃａｄｈｅｒｉｎ、Ｒ－Ｃａｄｈｅｒｉｎ、ＣＤ６８、ＣＤ１６３およびＣＳＦ１－Ｒ から選択される少なくとも２つの染色対象タンパク質に対してそれぞれ異なる色素を用いて多重染色を行い、前記染色対象タンパク質の少なくとも１つを、前記アミノクマリン化合物内包粒子を用いて染色する蛍光標識法を挙げることができる。 Preferable embodiments of the immunostaining method include PDL1, CTLA4, CD8, CD30, CD48, CD59, IDO, TDO, CSF-1R, HDAC, CXCR4, FLT-3, TIGIT, INF-α, INF-β, INF- ω, INF-ε, INF-κ, INF-γ, INF-λ CSF, EPO, EGF, FGF, PDGF, HGF, TGF, CD3, CD4, CD25, CD28, CD80, CD86, CD160, CD57, OX40 (CD134) ), OX40L (CD252), ICOS (CD278), ICOSL (CD275), CD155, CD226, CD112, CD27, CD70, 4-1BB (CD137), 4-1BBL (CD137L), GITR (CD357), GITRL, BTLA ( CD272), HVEM (CD270), TIM-3, Galle Cutin-9 (Galectin-9), LAG-3 (CD223), B7-H3 (CD276), B7-H4, B7-H5, CD40, CD40L, PD-1, PD-L2, 2B4 (CD244), KLRG- 1, multiple staining using different dyes for at least two proteins selected from E-cadherin, N-cadherin, R-cadherin, CD68, CD163 and CSF1-R, respectively, An example is a fluorescent labeling method in which at least one is stained with the aminocoumarin compound-encapsulated particles.

　本発明の蛍光標識法により蛍光標識を行うと、緑色の輝点が明瞭であり、多重標識の場合、他の色領域、たとえば赤色領域への漏れ込みが小さく、緑色の輝点と赤色の輝点との良好なバランスが得られる。 When fluorescent labeling is performed by the fluorescent labeling method of the present invention, a green bright spot is clear, and in the case of multiple labels, leakage into other color areas, for example, a red area is small, and a green bright spot and a red bright spot are detected. A good balance with the points is obtained.

　本発明の蛍光標識法は、下記式（１）または（２）で示される構造を有するアミノクマリン化合物またはその塩を母体粒子に内包してなるアミノクマリン化合物内包粒子を用いて標識を行う蛍光標識法である。 The fluorescent labeling method of the present invention is a fluorescent label for labeling using an aminocoumarin compound-encapsulated particle in which an aminocoumarin compound having a structure represented by the following formula (1) or (2) or a salt thereof is encapsulated in a base particle. Is the law.

Figure JPOXMLDOC01-appb-C000005
Figure JPOXMLDOC01-appb-C000005

Figure JPOXMLDOC01-appb-C000006
　式（１）中、１３個のＲは、それぞれ独立に水素原子またはメチル基を表わす。
　式（２）中、６個のＡは、それぞれ独立に水素原子またはメチル基を表わす。
Figure JPOXMLDOC01-appb-C000006
 In formula (1), 13 R's each independently represent a hydrogen atom or a methyl group.
In formula (2), six A's each independently represent a hydrogen atom or a methyl group.

　式（１）および（２）中、Ｑはイオウ原子、酸素原子またはＮ－Ｒ1を表わす。前記Ｒ1は水素原子またはメチル基を表わす。本発明のアミノクマリン化合物は、式（１）または（２）のＱがイオウ原子である場合、ベンゾチアゾール構造を有し、酸素原子である場合、ベンゾオキサゾール構造を有し、Ｎ－Ｒ1である場合、ベンゾイミダゾール構造を有することになる。 In the formulas (1) and (2), Q represents a sulfur atom, an oxygen atom or N—R 1 . R 1 represents a hydrogen atom or a methyl group. The aminocoumarin compound of the present invention has a benzothiazole structure when Q in formula (1) or (2) is a sulfur atom, and has a benzoxazole structure when Q is an oxygen atom, and N—R 1 In some cases, it will have a benzimidazole structure.

　式（１）および（２）に含まれるスルホン酸基ＳＯ3Ｈは、前記ベンゾチアゾール構造、ベンゾオキサゾール構造またはベンゾイミダゾール構造に含まれるベンゼン環が有する結合可能な４つの炭素原子のうちどの炭素原子に結合していてもよい。 The sulfonic acid group SO 3 H contained in the formulas (1) and (2) is any carbon atom among the four carbon atoms that can be bonded to the benzene ring contained in the benzothiazole structure, benzoxazole structure or benzimidazole structure. May be bonded to.

　式（１）で示される構造を有するアミノクマリン化合物と式（２）で示される構造を有するアミノクマリン化合物とは、スルホン化されたベンゾチアゾール残基、ベンゾオキサゾール残基またはベンゾイミダゾール残基を有するアミノクマリン構造を有する点において共通する。 The aminocoumarin compound having the structure represented by the formula (1) and the aminocoumarin compound having the structure represented by the formula (2) have a sulfonated benzothiazole residue, benzoxazole residue or benzimidazole residue. Common in that it has an aminocoumarin structure.

　式（１）で示される構造を有するアミノクマリン化合物は、クマリン構造に結合する窒素原子が、クマリン構造に含まれるベンゼン環の４つの炭素原子とともに、２つの６員環を形成している点、すなわちアミノクマリンのアミノ基がジュロリジン構造となっている点で公知のスルホン化クマリン系化合物と構造が相違する。 In the aminocoumarin compound having the structure represented by the formula (1), the nitrogen atom bonded to the coumarin structure forms two 6-membered rings together with the four carbon atoms of the benzene ring contained in the coumarin structure, That is, the structure is different from a known sulfonated coumarin compound in that the amino group of aminocoumarin has a julolidine structure.

　式（１）で示される構造を有するアミノクマリン化合物は、公知のスルホン化クマリン系化合物よりも、励起波長が長波長であり、最大励起強度を与える波長が４７５ｎｍ以上であり、たとえば４７５～５１０ｎｍである。また、本発明のアミノクマリン化合物は、発光波長も公知のスルホン化クマリン系化合物より長波長であり、最大発光強度を与える波長が５１０ｎｍ以上であり、たとえば５１０～５４０ｎｍである。 The aminocoumarin compound having the structure represented by the formula (1) has an excitation wavelength longer than that of a known sulfonated coumarin compound, and a wavelength giving a maximum excitation intensity is 475 nm or more, for example, at 475 to 510 nm. is there. The aminocoumarin compound of the present invention also has a longer emission wavelength than known sulfonated coumarin compounds, and the wavelength that gives the maximum emission intensity is 510 nm or more, for example, 510 to 540 nm.

　式（１）で表わされるアミノクマリン化合物は、該アミノクマリン化合物のスルホン基を水素原子で置換して形成されるアミノクマリン化合物に比較して、発光強度が強いという特徴を有する。 The aminocoumarin compound represented by the formula (1) has a feature that the emission intensity is higher than that of an aminocoumarin compound formed by substituting the sulfone group of the aminocoumarin compound with a hydrogen atom.

　式（１）で示される構造を有するアミノクマリン化合物は、たとえば、下記式（３）で示される構造を有するクマリン化合物をスルホン化する方法により製造することができる。具体的には、式（３）で示されるクマリン化合物０．１ｇに対して発煙硫酸を１ｍｌ加えて、０～１４０℃で、１～８時間反応させることにより製造することができる。 An aminocoumarin compound having a structure represented by the formula (1) can be produced, for example, by a method of sulfonating a coumarin compound having a structure represented by the following formula (3). Specifically, it can be produced by adding 1 ml of fuming sulfuric acid to 0.1 g of the coumarin compound represented by the formula (3) and reacting at 0 to 140 ° C. for 1 to 8 hours.

Figure JPOXMLDOC01-appb-C000007
（式（３）中のＲおよびＱは、それぞれ式（１）中のＲおよびＱと同義である。）
Figure JPOXMLDOC01-appb-C000007
 (R and Q in formula (3) have the same meanings as R and Q in formula (1), respectively).

　式（２）で示される構造を有するアミノクマリン化合物は、たとえば、下記式（４）で示される構造を有するクマリン化合物をスルホン化する方法により製造することができる。具体的には、式（４）で示されるクマリン化合物０．１ｇに対して発煙硫酸を１ｍｌ加えて、０～１４０℃で、１～８時間反応させることにより製造することができる。 An aminocoumarin compound having a structure represented by the formula (2) can be produced, for example, by a method of sulfonating a coumarin compound having a structure represented by the following formula (4). Specifically, it can be produced by adding 1 ml of fuming sulfuric acid to 0.1 g of the coumarin compound represented by formula (4) and reacting at 0 to 140 ° C. for 1 to 8 hours.

Figure JPOXMLDOC01-appb-C000008
（式（４）中のＡおよびＱは、それぞれ式（２）中のＲおよびＱと同義である。）
Figure JPOXMLDOC01-appb-C000008
 (A and Q in the formula (4) are respectively synonymous with R and Q in the formula (2).)

　前記アミノクマリン化合物内包粒子は、式（１）または式（２）で示される構造を有するアミノクマリン化合物と該アミノクマリン化合物を内包する母体粒子とを有する。
　アミノクマリン化合物を内包する母体粒子は、有機粒子または無機粒子であり、アミノクマリン化合物を内包できる限り特に制限はない。
　前記有機粒子としては、熱硬化性樹脂であることが好ましい。熱硬化性樹脂は三次元的な網目構造を有するので、これに包み込まれたアミノクマリン化合物は樹脂粒子から離脱しにくく、免疫染色等の蛍光標識において好適である。熱硬化性樹脂としては、メラミン樹脂、尿素樹脂、アニリン樹脂、グアナミン樹脂、フェノール樹脂、キシレン樹脂およびフラン樹脂等を挙げることができる。これらの中でも、メラミン樹脂、尿素樹脂等のアミノ樹脂は、色素の樹脂粒子からの離脱をより効果的に抑止できる点で、特に好ましい。 The aminocoumarin compound-encapsulated particles have an aminocoumarin compound having a structure represented by formula (1) or formula (2) and base particles encapsulating the aminocoumarin compound.
The base particles encapsulating the aminocoumarin compound are organic particles or inorganic particles, and are not particularly limited as long as the aminocoumarin compound can be encapsulated.
The organic particles are preferably thermosetting resins. Since the thermosetting resin has a three-dimensional network structure, the aminocoumarin compound encapsulated in the thermosetting resin is not easily detached from the resin particles, and is suitable for fluorescent labeling such as immunostaining. Examples of the thermosetting resin include melamine resin, urea resin, aniline resin, guanamine resin, phenol resin, xylene resin, and furan resin. Among these, amino resins such as melamine resin and urea resin are particularly preferable because they can more effectively suppress the release of the pigment from the resin particles.

　前記無機粒子としては、シリカ粒子、ガラス粒子等を例示できる。
　母体粒子に内包されるアミノクマリン化合物の量は、特に制限はなく、アミノクマリン化合物内包粒子を免疫染色等の蛍光標識に用いる場合に、検出可能な輝度を確保できる量であればよい。 Examples of the inorganic particles include silica particles and glass particles.
The amount of the aminocoumarin compound encapsulated in the base particle is not particularly limited, and may be an amount that can ensure a detectable luminance when the aminocoumarin compound-encapsulated particle is used for a fluorescent label such as immunostaining.

　アミノクマリン化合物内包粒子の平均粒径は、特に制限はないが、免疫染色等の蛍光標識に用いる場合には、通常２０～５００ｎｍ、好ましくは８０～２００ｎｍである。アミノクマリン化合物内包粒子の平均粒径が２００ｎｍを超えると標識性に問題が生じる場合があり、８０ｎｍ未満であると、視認性に問題が生じる場合がある。 The average particle diameter of the aminocoumarin compound-encapsulated particles is not particularly limited, but when used for fluorescent labeling such as immunostaining, it is usually 20 to 500 nm, preferably 80 to 200 nm. If the average particle size of the aminocoumarin compound-containing particles exceeds 200 nm, there may be a problem with labeling properties, and if it is less than 80 nm, there may be problems with visibility.

　上記平均粒径は、ＳＥＭ観察でアミノクマリン化合物内包粒子の１０００個について粒径を測定し、その平均値として算出される。
　アミノクマリン化合物内包粒子の製造方法は、特に制限されず、公知の方法を採用することができる。一般的には、アミノクマリン化合物の存在下に樹脂またはシリカ等の母体を形成し、アミノクマリン化合物を母体粒子の中に内包させる方法を用いることができる。 The average particle size is calculated as an average value obtained by measuring the particle size of 1000 aminocoumarin compound-encapsulated particles by SEM observation.
The production method of the aminocoumarin compound-encapsulated particles is not particularly limited, and a known method can be adopted. In general, a method of forming a matrix such as a resin or silica in the presence of an aminocoumarin compound and encapsulating the aminocoumarin compound in the matrix particles can be used.

　母体粒子が有機粒子である場合には、たとえば、乳化重合法により、母体粒子を合成するための（コ）モノマーを（共）重合させながら、アミノクマリン化合物を添加し、当該（共）重合体の内部または表面にアミノクマリン化合物を取り込ませる方法を用いることができる。 When the base particle is an organic particle, for example, an aminocoumarin compound is added while (co) polymerizing the (co) monomer for synthesizing the base particle by emulsion polymerization, and the (co) polymer is added. A method of incorporating an aminocoumarin compound into the inside or the surface of can be used.

　母体粒子がシリカ等の無機粒子である場合には、たとえば、ラングミュア ８巻 ２９２１ページ（１９９２）に記載されているＦＩＴＣ内包シリカナノ粒子の合成方法を参考にすることができる。ＦＩＴＣの代わりにアミノクマリン化合物を用いることでアミノクマリン化合物内包シリカナノ粒子を合成することができる。 In the case where the base particles are inorganic particles such as silica, for example, the method for synthesizing FITC-encapsulated silica nanoparticles described in Langmuir Vol. 8, Vol. 9, page 2921 (1992) can be referred to. Aminocoumarin compound-encapsulated silica nanoparticles can be synthesized by using an aminocoumarin compound instead of FITC.

　アミノクマリン化合物内包樹脂粒子は、最大励起強度を与える波長が４７５～５１０ｎｍであり、最大発光強度を与える波長が５１０～５４０ｎｍであることが好ましい。
　式（１）で表わされるアミノクマリン化合物を樹脂に内包させて製造されたアミノクマリン化合物内包樹脂粒子は、そのアミノクマリン化合物のスルホン基を水素原子で置換して形成されるアミノクマリン化合物を樹脂に内包させて製造されたアミノクマリン化合物内包樹脂粒子に比較して、発光強度が強い傾向がある。これは、式（１）で表わされるアミノクマリン化合物は、該アミノクマリン化合物のスルホン基を水素原子で置換して形成されるアミノクマリン化合物よりも、樹脂に内包されやすい性質があり、樹脂により多く取り込まれるからであると推測される。 In the aminocoumarin compound-encapsulating resin particles, the wavelength that gives the maximum excitation intensity is preferably 475 to 510 nm, and the wavelength that gives the maximum emission intensity is preferably 510 to 540 nm.
The aminocoumarin compound-encapsulating resin particle produced by encapsulating the aminocoumarin compound represented by the formula (1) in the resin is obtained by replacing the sulfone group of the aminocoumarin compound with a hydrogen atom. Compared with aminocoumarin compound-encapsulating resin particles produced by encapsulation, the emission intensity tends to be strong. This is because the aminocoumarin compound represented by the formula (1) is more easily included in the resin than the aminocoumarin compound formed by replacing the sulfone group of the aminocoumarin compound with a hydrogen atom. It is presumed that it is taken in.

　本発明の蛍光標識法は、前記アミノクマリン化合物内包粒子を用いて標識を行う。前記蛍光標識法としては、免疫染色法およびＦＩＳＨ等を挙げることができる。免疫染色法およびＦＩＳＨの具体的な操作方法は特に限定されず、公知の方法を用いることができる。色素粒子にて標識を行う従来の免疫染色法またはＦＩＳＨにおいて、前記色素粒子として前記アミノクマリン化合物内包粒子を使用すればよい。 In the fluorescent labeling method of the present invention, labeling is performed using the aminocoumarin compound-encapsulated particles. Examples of the fluorescent labeling method include immunostaining and FISH. The specific operation method of immunostaining and FISH is not particularly limited, and a known method can be used. In the conventional immunostaining method or FISH for labeling with dye particles, the aminocoumarin compound-encapsulated particles may be used as the dye particles.

　免疫染色法の場合、前記アミノクマリン化合物内包粒子を用いて、ＨＥＲ２およびＫｉ６７の他、ＰＤＬ１、ＣＴＬＡ４、ＣＤ８、ＣＤ３０、ＣＤ４８およびＣＤ５９などの染色対象タンパク質に対しても染色することができる。 In the case of immunostaining, the aminocoumarin compound-encapsulated particles can be used to stain not only HER2 and Ki67 but also proteins to be stained such as PDL1, CTLA4, CD8, CD30, CD48, and CD59.

　本発明の蛍光標識法は、前記アミノクマリン化合物内包粒子を用いた標識を含む多重標識であってもよい。すなわち、２つ以上の標識対象に対してそれぞれ異なる色素を用いて多重標識を行い、その染色対象の少なくとも１つを、前記アミノクマリン化合物内包粒子を用いて標識することができる。たとえば、複数の標識対象について、そのうちの一部の標識対象に対して前記アミノクマリン化合物内包粒子を用いて標識を行い、他の標識対象に対して緑色以外の発光を示す色素を含む粒子を用いて標識を行って、複数の標識対象を緑色と緑色以外の色とで別々に標識化することができる。 The fluorescent labeling method of the present invention may be a multiple label including a label using the aminocoumarin compound-encapsulated particles. That is, multiple labeling can be performed on two or more labeling targets using different dyes, and at least one of the staining targets can be labeled using the aminocoumarin compound-encapsulated particles. For example, for a plurality of labeling targets, some of the labeling targets are labeled using the aminocoumarin compound-containing particles, and particles containing a dye that emits light other than green are used for other labeling targets. Thus, a plurality of objects to be labeled can be separately labeled with green and a color other than green.

　たとえば、免疫染色法においては、ＰＤＬ１、ＣＴＬＡ４、ＣＤ８、ＣＤ３０、ＣＤ４８およびＣＤ５９から選択される少なくとも２つの染色対象タンパク質に対してそれぞれ異なる色素を用いて多重染色を行い、前記染色対象タンパク質の少なくとも１つを、前記アミノクマリン化合物内包粒子を用いて染色することができる。そうすれば、たとえば、ＰＤＬ１をアミノクマリン化合物内包粒子によって緑色に染色し、ＣＴＬＡ４を赤色で染色して、ＰＤＬ１とＣＴＬＡ４とを異なる色で標識化するということが可能になる。
　この多重染色においては、ＰＤＬ１、ＣＴＬＡ４、ＣＤ８、ＣＤ３０、ＣＤ４８、ＣＤ５９、ＩＤＯ、 ＴＤＯ、ＣＳＦ－１Ｒ、ＨＤＡＣ、ＣＸＣＲ４、ＦＬＴ－３、ＴＩＧＩＴ、ＩＮＦ-α、INF-β、INF-ω、INF-ε、INF-κ、INF-γ、INF-λ ＣＳＦ、ＥＰＯ、ＥＧＦ、ＦＧＦ、ＰＤＧＦ、ＨＧＦ、ＴＧＦ、ＣＤ３、ＣＤ４、ＣＤ２５、ＣＤ２８、ＣＤ８０、ＣＤ８６、ＣＤ１６０、ＣＤ５７、ＯＸ４０（別名ＣＤ１３４）、ＯＸ４０Ｌ（別名ＣＤ２５２）、ＩＣＯＳ（別名ＣＤ２７８）、ＩＣＯＳＬ（別名ＣＤ２７５）、ＣＤ１５５、ＣＤ２２６、ＣＤ１１２、ＣＤ２７、ＣＤ７０、４－１ＢＢ（別名ＣＤ１３７）、４－１ＢＢＬ（別名ＣＤ１３７Ｌ）、ＧＩＴＲ（別名ＣＤ３５７）、ＧＩＴＲＬ、ＢＴＬＡ（別名ＣＤ２７２）、ＨＶＥＭ（別名ＣＤ２７０）、ＴＩＭ－３、Ｇａｌｅｃｔｉｎ－９、ＬＡＧ－３（別名ＣＤ２２３）、Ｂ７－Ｈ３（別名ＣＤ２７６）、Ｂ７－Ｈ４、Ｂ７－Ｈ５、ＣＤ４０、ＣＤ４０Ｌ、ＰＤ－１、ＰＤ－Ｌ２、２Ｂ４（別名ＣＤ２４４）、ＫＬＲＧ－１、Ｅ－Ｃａｄｈｅｒｉｎ、Ｎ－Ｃａｄｈｅｒｉｎ、Ｒ－Ｃａｄｈｅｒｉｎ、ＣＤ６８、ＣＤ１６３およびＣＳＦ１－Ｒ から選択される少なくとも２つの染色対象タンパク質に対してそれぞれ異なる色素を用いて多重染色を行い、前記染色対象タンパク質の少なくとも１つを、前記アミノクマリン化合物内包粒子を用いて染色することができる。 For example, in the immunostaining method, multiple staining is performed on at least two proteins to be stained selected from PDL1, CTLA4, CD8, CD30, CD48 and CD59 using different dyes, and at least one of the proteins to be stained is selected. Can be dyed using the aminocoumarin compound-encapsulated particles. Then, for example, PDL1 can be stained green with aminocoumarin compound-encapsulated particles, CTLA4 can be stained with red, and PDL1 and CTLA4 can be labeled with different colors.
In this multiple staining, PDL1, CTLA4, CD8, CD30, CD48, CD59, IDO, TDO, CSF-1R, HDAC, CXCR4, FLT-3, TIGIT, INF-α, INF-β, INF-ω, INF- ε, INF-κ, INF-γ, INF-λ CSF, EPO, EGF, FGF, PDGF, HGF, TGF, CD3, CD4, CD25, CD28, CD80, CD86, CD160, CD57, OX40 (also known as CD134), OX40L (Aka CD252), ICOS (aka CD278), ICOSL (aka CD275), CD155, CD226, CD112, CD27, CD70, 4-1BB (aka CD137), 4-1BBL (aka CD137L), GITR (aka CD357), GITRL , BTLA (aka CD272), HVEM (aka CD2) 0), TIM-3, Galectin-9, LAG-3 (aka CD223), B7-H3 (aka CD276), B7-H4, B7-H5, CD40, CD40L, PD-1, PD-L2, 2B4 (aka alias) CD244), KLRG-1, E-Cadherin, N-Cadherin, R-Cadherin, CD68, CD163 and CSF1-R are subjected to multiple staining using different dyes, respectively, At least one of the proteins to be stained can be stained using the aminocoumarin compound-encapsulated particles.

　前記アミノクマリン化合物内包粒子を用いて標識を行うと、明瞭な緑色の輝点が確認でき、赤色領域などの他の色領域への漏れ込みが小さい。このため、特定の標識対象に対して前記アミノクマリン化合物内包粒子を用いて緑色の標識を行い、他の染色対象に対して赤色色素を含む色素粒子を用いて赤色の標識を行うと、得られる緑色の輝点は赤色領域への漏れ込みが小さく、緑色の輝点と赤色の輝点との良好なバランスが得られる。 When labeling is performed using the aminocoumarin compound-encapsulated particles, a clear green bright spot can be confirmed, and leakage into other color regions such as a red region is small. For this reason, it is obtained by labeling a specific labeling object with green using the aminocoumarin compound-encapsulating particles and labeling another staining object with red particles using a red pigment. The green luminescent spot has little leakage into the red region, and a good balance between the green luminescent spot and the red luminescent spot can be obtained.

　前記アミノクマリン化合物は、前記アミノクマリン化合物以外のクマリン化合物に比較して、赤色領域に近い発光領域を有するが、前記アミノクマリン化合物内包粒子を用いて標識を行うと、前記アミノクマリン化合物以外のクマリン化合物を含む色素粒子よりも、赤色領域への漏れ込みがむしろ小さいという効果が得られる。 The aminocoumarin compound has a light emitting region close to a red region as compared with a coumarin compound other than the aminocoumarin compound. When labeling is performed using the aminocoumarin compound-encapsulated particles, a coumarin other than the aminocoumarin compound is used. The effect that the leakage into the red region is rather smaller than that of the pigment particles containing the compound is obtained.

［合成例１］
　２０ｍＬバイアル管瓶に下記式（５）で表わされる化合物 ６００ｍｇを入れ、発煙硫酸６ｍＬを加えて、２５℃にて４時間撹拌し、反応を行った。反応の進行はＴＬＣにて確認した。具体的には、反応液の一部をＮａＯＨ水溶液にて中和した後、反応液にエタノールを加え、ＣＨＣｌ3　を２、ＭｅＯＨを３の割合で混合した溶液を用いてＴＬＣを行った。原料のＲｆ値０．８８に対し、目的物のＲｆ値０．７３であり、このＴＬＣのデータより、反応の収束および目的物の生成を確認した。 [Synthesis Example 1]
A 20 mL vial tube was charged with 600 mg of the compound represented by the following formula (5), 6 mL of fuming sulfuric acid was added, and the mixture was stirred at 25 ° C. for 4 hours to carry out the reaction. Progress of the reaction was confirmed by TLC. Specifically, a part of the reaction solution was neutralized with an aqueous NaOH solution, ethanol was added to the reaction solution, and TLC was performed using a solution in which CHCl 3 was mixed at a ratio of 2 and MeOH at a ratio of 3. The Rf value of the target product was 0.73 against the Rf value of 0.88 of the raw material, and the convergence of the reaction and the generation of the target product were confirmed from the TLC data.

　５０ｍＬバイアル管瓶に氷を８分目（３０ｍＬ）まで入れ、この中に反応液を少しずつ加えた。生成した色素が懸濁した懸濁液が得られた。この懸濁液を遠心分離し、上澄み液を除去して色素を沈殿として回収した。沈殿を純水１０ｍＬで分散し、この分散液を遠心分離して、上澄み液を除去して、沈殿を回収し、再度、純水１０ｍＬで分散し、この分散液を遠心分離して上澄み液を除去して、沈殿を回収した。回収した沈殿をエタノールで分散し、この分散液を遠心分離し、上澄み液を除去して、沈殿として下記式（Ｉ）で表わされるアミノクマリン化合物Ｉを得た。アミノクマリン化合物Ｉの収率は８０％であった。 Ice was put in a 50 mL vial tube until the 8th minute (30 mL), and the reaction solution was added little by little. A suspension in which the produced dye was suspended was obtained. The suspension was centrifuged, the supernatant was removed, and the dye was recovered as a precipitate. The precipitate is dispersed in 10 mL of pure water, the dispersion is centrifuged, the supernatant liquid is removed, the precipitate is recovered, dispersed again in 10 mL of pure water, and the dispersion is centrifuged to remove the supernatant. Removed and recovered the precipitate. The recovered precipitate was dispersed with ethanol, the dispersion was centrifuged, and the supernatant was removed to obtain an aminocoumarin compound I represented by the following formula (I) as a precipitate. The yield of aminocoumarin compound I was 80%.

　得られた沈殿物を乾燥後、得られた粉末を純水に加えた後、ＮａＯＨ水溶液で中和し、沈殿を溶解し、溶液のｐＨを７～８とした。この溶液を凍結乾燥機にて乾燥する事により、アミノクマリン化合物ＩのＮａ塩を得た。アミノクマリン化合物Ｉは、スルホン酸体では水への溶解性が悪いのに対し、Ｎａ塩とする事で、水に速やかに溶解することを確認した。 After the obtained precipitate was dried, the obtained powder was added to pure water, then neutralized with an aqueous NaOH solution to dissolve the precipitate, and the pH of the solution was adjusted to 7-8. This solution was dried with a freeze dryer to obtain Na salt of aminocoumarin compound I. It was confirmed that the aminocoumarin compound I dissolves quickly in water by using Na salt, whereas the sulfonic acid form has poor solubility in water.

Figure JPOXMLDOC01-appb-C000009
Figure JPOXMLDOC01-appb-C000009

Figure JPOXMLDOC01-appb-C000010
Figure JPOXMLDOC01-appb-C000010

［合成例２］
　式（５）で表わされる化合物の代わりに下記式（６）で表わされるアミノクマリン化合物ｉを用いたこと以外は製造例１と同様の方法により、下記式（ＩＩ）で表わされるアミノクマリン化合物ＩＩを得た。 [Synthesis Example 2]
The aminocoumarin compound II represented by the following formula (II) is prepared in the same manner as in Production Example 1 except that the aminocoumarin compound i represented by the following formula (6) is used instead of the compound represented by the formula (5). Got.

Figure JPOXMLDOC01-appb-C000011
Figure JPOXMLDOC01-appb-C000011

Figure JPOXMLDOC01-appb-C000012
Figure JPOXMLDOC01-appb-C000012

［合成例３］
　式（５）で表わされる化合物の代わりに下記式（７）で表わされるアミノクマリン化合物ｉを用いたこと以外は製造例１と同様の方法により、下記式（ＩＩＩ）で表わされるアミノクマリン化合物ＩＩＩを得た。 [Synthesis Example 3]
The aminocoumarin compound III represented by the following formula (III) was prepared in the same manner as in Production Example 1 except that the aminocoumarin compound i represented by the following formula (7) was used instead of the compound represented by the formula (5). Got.

Figure JPOXMLDOC01-appb-C000013
Figure JPOXMLDOC01-appb-C000013

Figure JPOXMLDOC01-appb-C000014
Figure JPOXMLDOC01-appb-C000014

［製造例１］
　アミノクマリン化合物Ｉ ３．４ｍｇに塩化チオニル０．１ｍLを加え、６５℃４時間、加熱混合した後、真空乾燥を行なって余剰の塩化チオニルを除去した。得られたアミノクマリン化合物と塩化チオニルの反応物と３－アミノプロピルトリメトキシシラン（３－ａｍｉｎｏｐｒｏｐｙｌｔｒｉｍｅｔｏｘｙｓｉｌａｎｅ、信越シリコーン社製、ＫＢＭ９０３）３μＬを１．２ｍＬのＮ,Ｎ－ジメチルホルムアミド（ＤＭＦ）の中で混合し、オルガノアルコキシシラン化合物を得た。 [Production Example 1]
After adding 0.1 mL of thionyl chloride to 3.4 mg of aminocoumarin compound I and heating and mixing at 65 ° C. for 4 hours, vacuum drying was performed to remove excess thionyl chloride. A reaction product of the obtained aminocoumarin compound and thionyl chloride and 3 μL of 3-aminopropyltrimethoxysilane (3-aminopropyltrimethoxysilane, manufactured by Shin-Etsu Silicone Co., Ltd., KBM903) in 1.2 mL of N, N-dimethylformamide (DMF) By mixing, an organoalkoxysilane compound was obtained.

　得られたオルガノアルコキシシラン化合物液０．３ｍＬを、９９％エタノール２４ｍＬ、テトラエトキシシラン（ＴＥＯＳ）０．３ｍＬ、超純水０．７５ｍＬ、および２８質量％のアンモニア水０．７５ｍＬと２５℃で３時間混合した。 The resulting organoalkoxysilane compound solution (0.3 mL) was mixed with 99% ethanol (24 mL), tetraethoxysilane (TEOS) (0.3 mL), ultrapure water (0.75 mL), and 28% by mass of ammonia water (0.75 mL) at 25 ° C. Mixed for hours.

　上記工程で作製した混合液を１００００Ｇで２０分間遠心分離し、上澄みを除去した。この沈殿に対して、エタノールを加えて、沈殿物を分散させ、再度遠心分離をするリンスを行った。さらに同様のリンスを２回繰り返し、アミノクマリン化合物内包粒子Ｉを得た。得られた粒子の１０００個についてＳＥＭ観察を行い、平均粒径を測定したところ、平均粒径は６０ｎｍであった。 The mixed solution prepared in the above step was centrifuged at 10,000 G for 20 minutes, and the supernatant was removed. To this precipitate, ethanol was added to disperse the precipitate, and rinsing was performed again by centrifugation. Further, similar rinsing was repeated twice to obtain aminocoumarin compound-encapsulated particles I. When 1000 particles of the obtained particles were observed with an SEM and the average particle size was measured, the average particle size was 60 nm.

［製造例２］
　超純水０．８５ｍＬ、アンモニア水０．８５ｍＬとしたこと以外は製造例１と同様の方法で、アミノクマリン化合物内包粒子ＩＩを得た。得られた粒子の１０００個についてＳＥＭ観察を行い、平均粒径を測定したところ、平均粒径は８０ｎｍであった。 [Production Example 2]
Aminocoumarin compound-encapsulated particles II were obtained in the same manner as in Production Example 1 except that 0.85 mL of ultrapure water and 0.85 mL of aqueous ammonia were used. When 1000 particles of the obtained particles were observed with an SEM and the average particle size was measured, the average particle size was 80 nm.

［製造例３］
　超純水１．１０ｍＬ、アンモニア水１．１０ｍＬとしたこと以外は製造例１と同様の方法で、アミノクマリン化合物内包粒子ＩＩＩを得た。得られた粒子の１０００個についてＳＥＭ観察を行い、平均粒径を測定したところ、平均粒径は１５０ｎｍであった。 [Production Example 3]
Aminocoumarin compound-encapsulated particles III were obtained in the same manner as in Production Example 1 except that the amount was 1.10 mL of ultrapure water and 1.10 mL of aqueous ammonia. When 1000 particles of the obtained particles were observed with an SEM and the average particle size was measured, the average particle size was 150 nm.

［製造例４］
　超純水１．１５ｍＬ、アンモニア水１．１５ｍＬとしたこと以外は製造例１と同様の方法で、アミノクマリン化合物内包粒子ＩＶを得た。得られた粒子の１０００個についてＳＥＭ観察を行い、平均粒径を測定したところ、平均粒径は１９５ｎｍであった。 [Production Example 4]
Aminocoumarin compound-encapsulated particles IV were obtained in the same manner as in Production Example 1, except that 1.15 mL of ultrapure water and 1.15 mL of aqueous ammonia were used. When 1,000 particles of the obtained particles were observed with an SEM and the average particle size was measured, the average particle size was 195 nm.

［製造例５］
　超純水１．２０ｍＬ、アンモニア水１．２０ｍＬとしたこと以外は製造例１と同様の方法で、アミノクマリン化合物内包粒子Ｖを得た。得られた粒子の１０００個についてＳＥＭ観察を行い、平均粒径を測定したところ、平均粒径は２２０ｎｍであった。 [Production Example 5]
Aminocoumarin compound-encapsulated particles V were obtained in the same manner as in Production Example 1 except that 1.20 mL of ultrapure water and 1.20 mL of aqueous ammonia were used. When 1000 particles of the obtained particles were observed with an SEM and the average particle size was measured, the average particle size was 220 nm.

［製造例６］
　アミノクマリン化合物Ｉの代わりにアミノクマリン化合物ＩＩを用いたこと以外は製造例３と同様の方法で、アミノクマリン化合物内包粒子ＶＩを得た。得られた粒子の１０００個についてＳＥＭ観察を行い、平均粒径を測定したところ、平均粒径は１５０ｎｍであった。 [Production Example 6]
Aminocoumarin compound-encapsulated particles VI were obtained in the same manner as in Production Example 3 except that aminocoumarin compound II was used instead of aminocoumarin compound I. When 1000 particles of the obtained particles were observed with an SEM and the average particle size was measured, the average particle size was 150 nm.

［製造例７］
　アミノクマリン化合物Ｉ　１４．４ｍｇを水２２ｍＬに加えて溶解させた。この溶液に乳化重合用乳化剤のエマルジョン（登録商標）４３０（ポリオキシエチレンオレイルエーテル、花王社製）の５％水溶液を２ｍＬ加えた。 [Production Example 7]
14.4 mg of aminocoumarin compound I was added to 22 mL of water and dissolved. To this solution, 2 mL of a 5% aqueous solution of an emulsion (registered trademark) 430 (polyoxyethylene oleyl ether, manufactured by Kao Corporation) of an emulsifier for emulsion polymerization was added.

　この溶液をホットスターラー上で撹拌しながら７０℃まで昇温させた後、この溶液にメラミン樹脂原料ニカラックＭＸ－０３５（日本カーバイド工業社製）を０．６５ｇ加えた。この溶液に反応開始剤としてドデシルベンゼンスルホン酸（関東化学社製）の１０％水溶液を１０００μＬ加え、７０℃で５０分間加熱撹拌し、その後、９０℃に昇温して２０分間加熱撹拌した。以上の操作により、アミノクマリン化合物内包粒子ＶＩＩを得た。 The solution was heated to 70 ° C. while stirring on a hot stirrer, and then 0.65 g of melamine resin raw material Nicalak MX-035 (manufactured by Nippon Carbide Industries Co., Ltd.) was added to the solution. To this solution was added 1000 μL of a 10% aqueous solution of dodecylbenzenesulfonic acid (manufactured by Kanto Chemical Co., Ltd.) as a reaction initiator, and the mixture was heated and stirred at 70 ° C. for 50 minutes, then heated to 90 ° C. and stirred for 20 minutes. By the above operation, aminocoumarin compound-encapsulated particles VII were obtained.

　得られたアミノクマリン化合物内包樹脂粒子ＶＩＩの分散液から、純水による洗浄を行い、余剰の樹脂原料やアミノクマリン化合物などの不純物を除いた。具体的には、遠心分離機（クボタ社製マイクロ冷却遠心機３７４０）にて２００００Ｇで１５分間、遠心分離し、上澄み除去後、超純水を加えて超音波照射して再分散した。遠心分離、上澄み除去および超純水への再分散による洗浄を５回繰り返した。
　アミノクマリン化合物内包粒子ＶＩＩの１０００個についてＳＥＭ観察を行い、平均粒径を測定したところ、平均粒径は１５０ｎｍであった。 The obtained dispersion liquid of aminocoumarin compound-encapsulating resin particles VII was washed with pure water to remove impurities such as excess resin material and aminocoumarin compound. Specifically, the mixture was centrifuged at 20000 G for 15 minutes in a centrifuge (Kubota Micro Cooling Centrifuge 3740), and after removing the supernatant, ultrapure water was added and ultrasonically irradiated to redisperse. Centrifugation, supernatant removal, and washing by redispersion in ultrapure water were repeated 5 times.
When 1000 particles of aminocoumarin compound-encapsulated particles VII were observed with SEM and the average particle size was measured, the average particle size was 150 nm.

［製造例８］
　アミノクマリン化合物Ｉの代わりにアミノクマリン化合物ＩＩを使用したこと以外は製造例７と同様の方法で、アミノクマリン化合物内包粒子ＶＩＩＩを得た。
　アミノクマリン化合物内包粒子ＶＩＩＩの１０００個についてＳＥＭ観察を行い、平均粒径を測定したところ、平均粒径は１５０ｎｍであった。 [Production Example 8]
Aminocoumarin compound-encapsulated particles VIII were obtained in the same manner as in Production Example 7 except that aminocoumarin compound II was used instead of aminocoumarin compound I.
SEM observation was performed on 1000 aminocoumarin compound-encapsulated particles VIII, and the average particle size was measured. As a result, the average particle size was 150 nm.

［製造例９］
　アミノクマリン化合物Ｉの代わりにアミノクマリン化合物ＩＩＩを使用したこと以外は製造例７と同様の方法で、アミノクマリン化合物内包粒子ＩＸを得た。
　アミノクマリン化合物内包粒子ＩＸの１０００個についてＳＥＭ観察を行い、平均粒径を測定したところ、平均粒径は１５０ｎｍであった。 [Production Example 9]
Aminocoumarin compound-encapsulated particles IX were obtained in the same manner as in Production Example 7 except that aminocoumarin compound III was used instead of aminocoumarin compound I.
SEM observation was performed on 1000 aminocoumarin compound-encapsulated particles IX, and the average particle size was measured. The average particle size was 150 nm.

［製造例１０］
　アミノクマリン化合物Ｉの代わりに緑色色素であるＰｙｒｒｏｍｅｔｈｅｎｅ５５６を用いたこと以外は製造例１と同様の方法で、色素内包粒子ｉを得た。得られた粒子の１０００個についてＳＥＭ観察を行い、平均粒径を測定したところ、平均粒径は１５０ｎｍであった。 [Production Example 10]
Dye-containing particles i were obtained in the same manner as in Production Example 1 except that Pyrromethene 556, which is a green pigment, was used instead of aminocoumarin compound I. When 1000 particles of the obtained particles were observed with an SEM and the average particle size was measured, the average particle size was 150 nm.

［製造例１１］
　アミノクマリン化合物Ｉの代わりに緑色色素であるＰｙｒｒｏｍｅｔｈｅｎｅ５５６を用いたこと以外は製造例７と同様の方法で、色素内包粒子ｉｉを得た。得られた粒子の１０００個についてＳＥＭ観察を行い、平均粒径を測定したところ、平均粒径は１５０ｎｍであった。 [Production Example 11]
Dye-encapsulated particles ii were obtained in the same manner as in Production Example 7 except that Pyrromethene 556, which is a green pigment, was used instead of aminocoumarin compound I. When 1000 particles of the obtained particles were observed with an SEM and the average particle size was measured, the average particle size was 150 nm.

［製造例１２］
　アミノクマリン化合物Ｉの代わりに赤色色素であるスルホローダミン１０１を用いたこと以外は製造例７と同様の方法で、色素内包粒子ｉｉｉを得た。得られた粒子の１０００個についてＳＥＭ観察を行い、平均粒径を測定したところ、平均粒径は１５０ｎｍであった。 [Production Example 12]
Dye-containing particles iii were obtained in the same manner as in Production Example 7 except that sulforhodamine 101, which is a red dye, was used instead of aminocoumarin compound I. When 1000 particles of the obtained particles were observed with an SEM and the average particle size was measured, the average particle size was 150 nm.

［実施例１］
　下記の方法により免疫染色を行った。
（色素内包粒子のストレプトアビジン修飾）
　アミノクマリン化合物内包粒子Ｉを、ＥＤＴＡ（エチレンジアミン四酢酸）を２ｍＭ含有するＰＢＳ（リン酸緩衝液生理的食塩水）を用いて３ｎＭに調整し、この溶液に最終濃度１０ｍＭとなるようにＳＭ（ＰＥＧ）12（サーモサイエンティフィック社製、ｓｕｃｃｉｎｉｍｉｄｙｌ－［（Ｎ－ｍａｌｅｉｍｉｄｏｐｒｏｐｉｏｎａｍｉｄ）－ｄｏｄｅｃａｎｅｔｈｙｌｅｎｅｇｌｙｃｏｌ］ｅｓｔｅｒ）を混合し、５℃で１時間反応させた。 [Example 1]
Immunostaining was performed by the following method.
(Modification of dye-encapsulated particles with streptavidin)
Aminocoumarin compound-encapsulated particles I were adjusted to 3 nM using PBS (phosphate buffered saline) containing 2 mM of EDTA (ethylenediaminetetraacetic acid), and SM (PEG) was added to this solution to a final concentration of 10 mM. ) 12 (manufactured by Thermo Scientific, succinimidyl-[(N-maleimidopropionamid) -dodecaneethyleneglycol] ester) was mixed and reacted at 5 ° C. for 1 hour.

　この混合液を、１００００Ｇで２０分遠心分離を行い、上澄みを除去した後に、ＥＤＴＡを２ｍＭ含有したＰＢＳを加え、沈降物を分散させ、再度遠心分離を行った。同様の手順による洗浄を３回行うことで末端にマレイミド基がついたアミノクマリン化合物内包粒子Ｉを得た。 The mixture was centrifuged at 10,000 G for 20 minutes, the supernatant was removed, PBS containing 2 mM of EDTA was added, the precipitate was dispersed, and the mixture was centrifuged again. By performing washing by the same procedure three times, aminocoumarin compound-encapsulated particles I having a maleimide group at the end were obtained.

　１ｍｇ／ｍＬに調整したストレプトアビジン（和光純薬工業社製）４０μＬを２１０μＬのボレートバッファーに加えた後、６４ｍｇ／ｍＬに調整した２－イミノチオラン塩酸塩（シグマアルドリッチ社製）７０μＬを加え、室温で1時間反応させた。これにより、ストレプトアビジンのアミノ基に対してチオール基（－NH－C（＝NH2 +Cl-）－CH2－CH2－CH2－SH）を導入した。 40 μL of streptavidin adjusted to 1 mg / mL (manufactured by Wako Pure Chemical Industries, Ltd.) was added to 210 μL of borate buffer, and then 70 μL of 2-iminothiolane hydrochloride (Sigma Aldrich) adjusted to 64 mg / mL was added at room temperature. Reacted for 1 hour. Thereby, a thiol group (—NH—C (═NH 2 + Cl − ) —CH 2 —CH 2 —CH 2 —SH) was introduced to the amino group of streptavidin.

　このストレプトアビジン溶液をゲルろ過カラム（Ｚａｂａ　Ｓｐｉｎ　Ｄｅｓａｌｔｉｎｇ　Ｃｏｌｕｍｎｓ：フナコシ）により脱塩し、上記シリカ系粒子に結合可能なストレプトアビジンを得た。このストレプトアビジン全量（０．０４ｍｇ含有)とＥＤＴＡを２ｍＭ含有したＰＢＳを用いて上記０．６７ｎＭに調整したシリカ系粒子７４０μＬとを混合し、室温で１時間反応させた。 The streptavidin solution was desalted with a gel filtration column (Zaba Spin Desaling Columns: Funakoshi) to obtain streptavidin capable of binding to the silica particles. This total amount of streptavidin (containing 0.04 mg) was mixed with 740 μL of the silica-based particles adjusted to 0.67 nM using PBS containing 2 mM of EDTA, and reacted at room temperature for 1 hour.

　１０ｍＭメルカプトエタノールを添加し、反応を停止させた。得られた溶液を遠心フィルターで濃縮後、精製用ゲルろ過カラムを用いて未反応ストレプトアビジン等を除去し、ストレプトアビジン結合アミノクマリン化合物内包粒子Ｉを得た。 10 mM mercaptoethanol was added to stop the reaction. After the resulting solution was concentrated with a centrifugal filter, unreacted streptavidin and the like were removed using a gel filtration column for purification to obtain streptavidin-linked aminocoumarin compound-encapsulated particles I.

（ビオチン修飾された２次抗体の作製）
　５０ｍＭＴｒｉｓ－ＨＣｌ溶液（ｐＨ７．５）に抗ウサギＩｇＧ抗体５０μｇを溶解した。該溶液に、最終濃度３ｍＭとなるようにＤＴＴ（ｄｉｔｈｉｏｔｈｒｅｔｏｌ）溶液を混合した。その後、該溶液を３７℃で３０分間反応させた。その後、脱塩カラムを用いてＤＴＴで還元化した２次抗体を精製した。精製した抗体全量のうち２００μＬを５０ｍＭＴｒｉｓ－ＨＣｌ溶液（ｐＨ７．５）に溶解して抗体溶液を得た。その一方で、スペーサーの長さが３０オングストロームであるリンカー試薬「（＋）－Ｂｉｏｔｉｎ－ＰＥＧ6‐ＮＨ‐Ｍａｌ」（ＰｕｒｅＰＥＧ社製,製品番号2461006-250）を、ＤＭＳＯを用いて０．４ｍＭとなるように調整した。この溶液８．５μＬを前記抗体溶液に添加し、混和して３７℃で３０分間反応させた。 (Production of biotin-modified secondary antibody)
50 μg of anti-rabbit IgG antibody was dissolved in 50 mM Tris-HCl solution (pH 7.5). A DTT (dithiothritol) solution was mixed with the solution so as to have a final concentration of 3 mM. Thereafter, the solution was reacted at 37 ° C. for 30 minutes. Thereafter, the secondary antibody reduced with DTT was purified using a desalting column. 200 μL of the total amount of the purified antibody was dissolved in a 50 mM Tris-HCl solution (pH 7.5) to obtain an antibody solution. On the other hand, a linker reagent “(+)-Biotin-PEG 6 -NH-Mal” (manufactured by PurePEG, product number 2461006-250) having a spacer length of 30 angstroms was adjusted to 0.4 mM using DMSO. It adjusted so that it might become. 8.5 μL of this solution was added to the antibody solution, mixed and allowed to react at 37 ° C. for 30 minutes.

　この反応溶液を脱塩カラム「Zeba Desalt Spin Columns」（サーモサイエンティフィック社製，Cat.#89882）に供して精製した。脱塩した反応溶液の波長３００ｎｍの吸収を分光高度計（日立製「Ｆ－７０００」）により計測して反応溶液に含まれるタンパク質の量を算出した。５０ｍＭＴｒｉｓ溶液により反応溶液を２５０μｇ／ｍＬに調整し、該溶液をビオチン化２次抗体の溶液とした。 The reaction solution was purified by subjecting it to a desalting column “Zeba Desalt Spin Spin Columns” (Thermo Scientific Cat. # 89882). Absorption at a wavelength of 300 nm of the desalted reaction solution was measured with a spectrophotometer (Hitachi “F-7000”) to calculate the amount of protein contained in the reaction solution. The reaction solution was adjusted to 250 μg / mL with a 50 mM Tris solution, and this solution was used as a biotinylated secondary antibody solution.

（染色）
　（１）標本処理工程
　（１－１）脱パラフィン処理工程
　染色用の組織切片として、ＨＥＲ２（３＋）とＨＥＲ２（－）の組織アレイスライド（コスモバイオ社製「ＣＢ－Ａ７１２のシリーズ」）を用いた。この組織アレイスライドを脱パラフィン処理した。 (staining)
(1) Specimen processing step (1-1) Deparaffinization processing step HER2 (3+) and HER2 (-) tissue array slides ("CB-A712 series" manufactured by Cosmo Bio) are used as tissue sections for staining. It was. The tissue array slide was deparaffinized.

　（１－２）賦活化処理工程
　脱パラフィン処理した組織アレイスライドを水に置換する洗浄を行った。洗浄した組織アレイスライドを１０ｍＭクエン酸緩衝液中（ｐＨ６．０）中で１２１℃、１５分間オートクレーブ処理することで、抗原の賦活化処理を行った。賦活化処理後の組織アレイスライドをＰＢＳにより洗浄し、洗浄した組織アレイスライドに対してＢＳＡを１％含有するＰＢＳを用いて１時間ブロッキング処理を行った。 (1-2) Activation treatment step Washing was performed by replacing the deparaffinized tissue array slide with water. The washed tissue array slide was autoclaved at 121 ° C. for 15 minutes in 10 mM citrate buffer (pH 6.0) to activate the antigen. The tissue array slide after the activation treatment was washed with PBS, and the washed tissue array slide was subjected to blocking treatment with PBS containing 1% BSA for 1 hour.

　（２）免疫染色処理工程
　（２－１）１次反応
　ＢＳＡを１％含有するＰＢＳを用いて、ベンタナ社製「抗ＨＥＲ２ウサギモノクロナール抗体（４Ｂ５）」を０．０５ｎＭに調整し、該１次抗体の溶液を上述のブロッキング処理した組織アレイスライドに対して４℃で１晩反応させた。 (2) Immunostaining treatment step (2-1) Primary reaction “Anti-HER2 rabbit monoclonal antibody (4B5)” manufactured by Ventana was adjusted to 0.05 nM using PBS containing 1% BSA. The next antibody solution was reacted overnight at 4 ° C. against the above-blocked tissue array slide.

　（２－２）２次反応
　１次反応を行った組織アレイスライドをＰＢＳで洗浄した後、１％ＢＳＡ含有のＰＢＳで６μｇ／ｍＬに希釈した上記ビオチン化２次抗体と室温３０分間反応させた。 (2-2) Secondary reaction The tissue array slide subjected to the primary reaction was washed with PBS, and then reacted with the biotinylated secondary antibody diluted to 6 μg / mL with PBS containing 1% BSA for 30 minutes at room temperature. .

　（２－３）蛍光標識処理
　２次反応を行った組織アレイスライドに対して、１％ＢＳＡ含有のＰＢＳで０．０２ｎＭに希釈したストレプトアビジン結合アミノクマリン化合物内包粒子Ｉを、中性のｐＨ環境（ｐＨ６．９～７.４）室温の条件下で３時間反応させた。該反応後の組織アレイスライドをＰＢＳで洗浄した。 (2-3) Fluorescence labeling treatment The tissue array slide subjected to the secondary reaction was subjected to neutral pH environment using streptavidin-conjugated aminocoumarin compound-encapsulated particles I diluted to 0.02 nM with PBS containing 1% BSA. (PH 6.9 to 7.4) The reaction was performed at room temperature for 3 hours. The tissue array slide after the reaction was washed with PBS.

　（３）形態観察染色工程
　免疫染色後、ヘマトキシリン・エオシン染色（ＨＥ染色）を行った。免疫染色した切片をマイヤーヘマトキシリン液で５分間染色してヘマトキシリン染色を行った。その後、該組織切片を４５℃の流水で３分間洗浄した。次に、１％エオシン液で５分間染色してエオシン染色を行った。 (3) Morphological Observation Staining Step After immunostaining, hematoxylin / eosin staining (HE staining) was performed. The immunostained sections were stained with Mayer's hematoxylin solution for 5 minutes to perform hematoxylin staining. Thereafter, the tissue section was washed with running water at 45 ° C. for 3 minutes. Next, eosin staining was performed by staining with 1% eosin solution for 5 minutes.

　（４）固定処理工程
　免疫染色工程および形態観察染色工程を終えた組織切片に対して、純エタノールに５分間浸漬する操作を４回行い、洗浄・脱水を行った。続いて、キシレンに５分間浸漬する操作を４回行い、透徹を行った。最後に、封入剤（メルク社製「エンテランニュー」）を用いて、組織切片を封入して観察用のサンプルの組織アレイスライドとした。 (4) Fixing treatment step The tissue sections that had undergone the immunostaining step and the morphological observation staining step were immersed in pure ethanol for 5 minutes four times, and washed and dehydrated. Subsequently, the operation of immersing in xylene for 5 minutes was carried out 4 times to perform clearing. Finally, a tissue section slide of a sample for observation was prepared by enclosing a tissue section using an encapsulant (“Enteran New” manufactured by Merck).

　（５）観察・計測工程
　固定化処理工程を終えた組織切片に対して所定の励起光を照射して、蛍光を発光させた。その状態の組織切片を蛍光顕微鏡（オリンパス社製「ＢＸ－５３」）、顕微鏡用デジタルカメラ（オリンパス社製「ＤＰ７３」）により観察および撮像を行った。上記励起光は、光学フィルターに通すことで５７５～６００ｎｍに設定した。また、観察する蛍光の波長（ｎｍ）の範囲についても、光学フィルターを通すことで６１２～６９２ｎｍに設定した。顕微鏡観察、画像取得時の励起波長の条件は、５８０ｎｍの励起では視野中心部付近の照射エネルギーが９００Ｗ／ｃｍ2となるようにした。画像取得時の露光時間は、画像の輝度が飽和しないように任意に設定（例えば４０００μ秒に設定）して撮像した。ＨＥＲ２（３＋）の組織の輝点数は、４００倍で撮像した画像をもとにＩｍａｇｅＪ　ＦｉｎｄＭａｘｉｍｓ法により計測した１０００細胞の平均値とした。
　視野内の細胞膜上の輝点数Ｓおよび視野内の細胞外の輝点数Ｎを測定し、Ｓ／Ｎを算出した。Ｓ／Ｎを表１に示す。 (5) Observation / Measurement Step The tissue section after the immobilization treatment step was irradiated with predetermined excitation light to emit fluorescence. The tissue sections in this state were observed and imaged with a fluorescence microscope (OLYMPUS "BX-53") and a digital camera for microscope (OLYMPUS "DP73"). The excitation light was set to 575 to 600 nm by passing through an optical filter. The range of the wavelength (nm) of fluorescence to be observed was also set to 612 to 692 nm by passing through an optical filter. The conditions of the excitation wavelength during microscopic observation and image acquisition were such that the irradiation energy near the center of the field of view was 900 W / cm 2 for excitation at 580 nm. The exposure time at the time of image acquisition was arbitrarily set so as not to saturate the brightness of the image (for example, set to 4000 μsec) and imaged. The number of bright spots of the HER2 (3+) tissue was an average value of 1000 cells measured by the ImageJ FindMaxims method based on an image captured at 400 times.
The number S of bright spots on the cell membrane in the field of view and the number N of bright spots outside the field in the field of view were measured, and S / N was calculated. S / N is shown in Table 1.

［実施例２～５、７、８］
（色素内包粒子のストレプトアビジン修飾）
　実施例２～５、７、８においては、アミノクマリン化合物内包粒子Ｉの代わりにアミノクマリン化合物内包粒子ＩＩ～ＶＩ、ＶＩＩＩをそれぞれ使用したこと以外は実施例１と同様の方法でストレプトアビジン結合アミノクマリン化合物内包粒子ＩＩ～ＶＩ、ＶＩＩＩをそれぞれ得た。 [Examples 2 to 5, 7, 8]
(Modification of dye-encapsulated particles with streptavidin)
In Examples 2-5, 7, and 8, streptavidin-linked amino acid was prepared in the same manner as in Example 1 except that aminocoumarin compound-encapsulated particles II to VI and VIII were used instead of aminocoumarin compound-encapsulated particle I, respectively. Coumarin compound-encapsulated particles II to VI and VIII were obtained, respectively.

（ビオチン修飾された２次抗体の作製）
　実施例２～５、７、８においては、実施例１と同様の方法でビオチン化２次抗体の溶液を得た。 (Production of biotin-modified secondary antibody)
In Examples 2 to 5, 7, and 8, biotinylated secondary antibody solutions were obtained in the same manner as in Example 1.

（染色）
　実施例２～５、７、８においては、ストレプトアビジン結合アミノクマリン化合物内包粒子Ｉの代わりにストレプトアビジン結合アミノクマリン化合物内包粒子ＩＩ～ＶＩ、ＶＩＩＩをそれぞれ使用したこと以外は実施例１と同様の方法で、Ｓ／Ｎを算出した。Ｓ／Ｎを表１に示す。 (staining)
Examples 2 to 5, 7, and 8 were the same as Example 1 except that streptavidin-conjugated aminocoumarin compound-encapsulated particles I were used instead of streptavidin-conjugated aminocoumarin compound-encapsulated particles I, respectively. S / N was calculated by the method. S / N is shown in Table 1.

［実施例６］
（色素内包粒子のストレプトアビジン修飾）
　アミノクマリン化合物内包粒子Ｉの代わりにアミノクマリン化合物内包粒子ＩＩＩを使用したこと以外は実施例１と同様の方法でストレプトアビジン結合アミノクマリン化合物内包粒子ＩＩＩを得た。
（ビオチン修飾された２次抗体の作製）
　実施例１と同様の方法でビオチン化２次抗体の溶液を得た。 [Example 6]
(Modification of dye-encapsulated particles with streptavidin)
Streptavidin-linked aminocoumarin compound-encapsulated particles III were obtained in the same manner as in Example 1 except that aminocoumarin compound-encapsulated particles III were used instead of aminocoumarin compound-encapsulated particles I.
(Production of biotin-modified secondary antibody)
A biotinylated secondary antibody solution was obtained in the same manner as in Example 1.

（染色）
　（１）標本処理工程
　（１－１）脱パラフィン処理工程
　染色用の組織切片としてＰＤＬ１の組織アレイスライドを用いた。この組織アレイスライドを脱パラフィン処理した。 (staining)
(1) Specimen Processing Step (1-1) Deparaffinization Processing Step A tissue array slide of PDL1 was used as a tissue section for staining. The tissue array slide was deparaffinized.

　（１－２）賦活化処理工程
　脱パラフィン処理した組織アレイスライドを水に置換する洗浄を行った。洗浄した組織アレイスライドを１０ｍＭクエン酸緩衝液（ｐＨ６．０）中で１２１℃、１５分間オートクレーブ処理することで、抗原の賦活化処理を行った。賦活化処理後の組織アレイスライドをＰＢＳにより洗浄し、洗浄した組織アレイスライドに対してＢＳＡを１％含有するＰＢＳを用いて１時間ブロッキング処理を行った。 (1-2) Activation treatment step Washing was performed by replacing the deparaffinized tissue array slide with water. The washed tissue array slide was autoclaved in a 10 mM citrate buffer (pH 6.0) at 121 ° C. for 15 minutes to activate the antigen. The tissue array slide after the activation treatment was washed with PBS, and the washed tissue array slide was subjected to blocking treatment with PBS containing 1% BSA for 1 hour.

　（２）免疫染色処理工程
　（２－１）１次反応
　ＢＳＡを１％含有するＰＢＳを用いて、Cell Signaling Technology社製「抗PD-L1ウサギモノクロナール抗体(E1L3N)」を０．０５ｎＭに調整し、該１次抗体の溶液を上述のブロッキング処理した組織アレイスライドに対して４℃で１晩反応させた。 (2) Immunostaining treatment step (2-1) Primary reaction “Anti-PD-L1 rabbit monoclonal antibody (E1L3N)” manufactured by Cell Signaling Technology was adjusted to 0.05 nM using PBS containing 1% BSA. Then, the primary antibody solution was reacted overnight at 4 ° C. against the above-mentioned blocked tissue array slide.

　（２－２）２次反応
　１次反応を行った組織アレイスライドをＰＢＳで洗浄した後、１％ＢＳＡ含有のＰＢＳで６μｇ／ｍＬに希釈した上記ビオチン化２次抗体と室温３０分間反応させた。 (2-2) Secondary reaction The tissue array slide subjected to the primary reaction was washed with PBS, and then reacted with the biotinylated secondary antibody diluted to 6 μg / mL with PBS containing 1% BSA for 30 minutes at room temperature. .

　（２－３）蛍光標識処理
　２次反応を行った組織アレイスライドに対して、１％ＢＳＡ含有のＰＢＳで０．０２ｎＭに希釈したストレプトアビジン結合アミノクマリン化合物内包粒子ＩＩＩを、中性のｐＨ環境（ｐＨ６．９～７.４）室温の条件下で３時間反応させた。該反応後の組織アレイスライドをＰＢＳで洗浄した。 (2-3) Fluorescence labeling treatment The tissue array slide subjected to the secondary reaction was subjected to neutral pH environment using streptavidin-conjugated aminocoumarin compound-encapsulated particles III diluted to 0.02 nM with PBS containing 1% BSA. (PH 6.9 to 7.4) The reaction was performed at room temperature for 3 hours. The tissue array slide after the reaction was washed with PBS.

　（３）形態観察染色工程
　免疫染色後、ヘマトキシリン・エオシン染色（ＨＥ染色）を行った。免疫染色した切片をマイヤーヘマトキシリン液で５分間染色してヘマトキシリン染色を行った。その後、該組織切片を４５℃の流水で３分間洗浄した。次に、１％エオシン液で５分間染色してエオシン染色を行った。 (3) Morphological Observation Staining Step After immunostaining, hematoxylin / eosin staining (HE staining) was performed. The immunostained sections were stained with Mayer's hematoxylin solution for 5 minutes to perform hematoxylin staining. Thereafter, the tissue section was washed with running water at 45 ° C. for 3 minutes. Next, eosin staining was performed by staining with 1% eosin solution for 5 minutes.

　（４）固定処理工程
　免疫染色工程および形態観察染色工程を終えた組織切片に対して、純エタノールに５分間浸漬する操作を４回行い、洗浄・脱水を行った。続いて、キシレンに５分間浸漬する操作を４回行い、透徹を行った。最後に、封入剤（メルク社製「エンテランニュー」）を用いて、組織切片を封入して観察用のサンプルの組織アレイスライドとした。 (4) Fixing treatment step The tissue sections that had undergone the immunostaining step and the morphological observation staining step were immersed in pure ethanol for 5 minutes four times, and washed and dehydrated. Subsequently, the operation of immersing in xylene for 5 minutes was carried out 4 times to perform clearing. Finally, a tissue section slide of a sample for observation was prepared by enclosing a tissue section using an encapsulant (“Enteran New” manufactured by Merck).

　（５）観察・計測工程
　実施例１と同様の方法で、Ｓ／Ｎを算出した。Ｓ／Ｎを表１に示す。 (5) Observation / Measurement Step S / N was calculated by the same method as in Example 1. S / N is shown in Table 1.

［実施例９］
（色素内包粒子のストレプトアビジン修飾）
　アミノクマリン化合物内包粒子Ｉの代わりにアミノクマリン化合物内包粒子ＶＩＩＩを使用したこと以外は実施例１と同様の方法でストレプトアビジン結合アミノクマリン化合物内包粒子ＶＩＩＩを得た。 [Example 9]
(Modification of dye-encapsulated particles with streptavidin)
Streptavidin-linked aminocoumarin compound-encapsulated particles VIII were obtained in the same manner as in Example 1 except that aminocoumarin compound-encapsulated particles VIII were used instead of aminocoumarin compound-encapsulated particles I.

（ビオチン修飾された２次抗体の作製）
　実施例１と同様の方法でビオチン化２次抗体の溶液を得た。
（染色）
　ストレプトアビジン結合アミノクマリン化合物内包シリカナノ粒子ＩＩＩの代わりにストレプトアビジン結合アミノクマリン化合物内包粒子ＶＩＩＩを使用したこと以外は実施例６と同様の方法で、Ｓ／Ｎを算出した。Ｓ／Ｎを表１に示す。 (Production of biotin-modified secondary antibody)
A biotinylated secondary antibody solution was obtained in the same manner as in Example 1.
(staining)
S / N was calculated in the same manner as in Example 6 except that streptavidin-linked aminocoumarin compound-encapsulated particles VIII were used instead of streptavidin-linked aminocoumarin compound-encapsulated silica nanoparticles III. S / N is shown in Table 1.

［比較例１］
（色素内包粒子のストレプトアビジン修飾）
　アミノクマリン化合物内包粒子Ｉの代わりに色素内包粒子ｉを使用したこと以外は実施例１と同様の方法でストレプトアビジン結合色素内包粒子ｉを得た。 [Comparative Example 1]
(Modification of dye-encapsulated particles with streptavidin)
Streptavidin-binding dye-encapsulated particles i were obtained in the same manner as in Example 1 except that the dye-encapsulated particles i were used in place of the aminocoumarin compound-encapsulated particles I.

（ビオチン修飾された２次抗体の作製）
　実施例１と同様の方法でビオチン化２次抗体の溶液を得た。
（染色）
　ストレプトアビジン結合アミノクマリン化合物内包粒子Ｉの代わりにストレプトアビジン結合色素内包粒子ｉを使用したこと以外は実施例１と同様の方法で、Ｓ／Ｎを算出した。Ｓ／Ｎを表１に示す。 (Production of biotin-modified secondary antibody)
A biotinylated secondary antibody solution was obtained in the same manner as in Example 1.
(staining)
S / N was calculated in the same manner as in Example 1 except that streptavidin-conjugated dye-encapsulated particles i were used instead of streptavidin-conjugated aminocoumarin compound-encapsulated particles I. S / N is shown in Table 1.

［比較例２］
（色素内包粒子のストレプトアビジン修飾）
　アミノクマリン化合物内包粒子Ｉの代わりに色素内包粒子ｉを使用したこと以外は実施例１と同様の方法でストレプトアビジン結合色素内包粒子ｉを得た。 [Comparative Example 2]
(Modification of dye-encapsulated particles with streptavidin)
Streptavidin-binding dye-encapsulated particles i were obtained in the same manner as in Example 1 except that the dye-encapsulated particles i were used in place of the aminocoumarin compound-encapsulated particles I.

（ビオチン修飾された２次抗体の作製）
　実施例１と同様の方法でビオチン化２次抗体の溶液を得た。
（染色）
　ストレプトアビジン結合アミノクマリン化合物内包粒子ＩＩＩの代わりにストレプトアビジン結合色素内包粒子ｉを使用したこと以外は実施例６と同様の方法で、Ｓ／Ｎを算出した。Ｓ／Ｎを表１に示す。 (Production of biotin-modified secondary antibody)
A biotinylated secondary antibody solution was obtained in the same manner as in Example 1.
(staining)
S / N was calculated in the same manner as in Example 6 except that streptavidin-linked dye-encapsulated particles i were used instead of streptavidin-conjugated aminocoumarin compound-encapsulated particles III. S / N is shown in Table 1.

Figure JPOXMLDOC01-appb-T000015
Figure JPOXMLDOC01-appb-T000015

　表１より、式（１）または（２）で示される構造を有するアミノクマリン化合物Ｉ～ＩＩＩを内包したアミノクマリン化合物内包粒子を用いて免疫染色を行うと、式（１）または（２）で示される構造を有するアミノクマリン化合物以外の色素であるＰｙｒｒｏｍｅｔｈｅｎｅ５５６を内包した色素内包粒子を用いた場合に比較して、Ｓ／Ｎが向上することが確認された。 From Table 1, when immunostaining was performed using aminocoumarin compound-encapsulated particles encapsulating aminocoumarin compounds I to III having the structure represented by formula (1) or (2), the formula (1) or (2) It was confirmed that the S / N ratio was improved as compared with the case of using the dye-encapsulated particles encapsulating Pyrromethene 556, which is a dye other than the aminocoumarin compound having the structure shown.

［実施例１０］
　下記の方法により緑色および赤色の多重免疫染色を行った。
（色素内包粒子の修飾）
　アミノクマリン化合物内包樹脂粒子ＶＩＩの末端にＮＨＳ－ＰＥＧ（polyethylene glycol）－マレイミド試薬を用いてマレイミドを導入し、これにチオール化した抗ＨＥＲ２抗体を結合させ、抗ＨＥＲ２抗体結合アミノクマリン化合物内包樹脂粒子を作製した。
　上記と同様に、色素内包粒子ｉｉｉの末端にマレイミドを導入し、これにチオール化した抗Ｋｉ６７抗体を結合させ、抗Ｋｉ６７抗体結合色素内包粒子を作製した。 [Example 10]
Multiple immunostaining of green and red was performed by the following method.
(Modification of dye-containing particles)
Aminocoumarin compound-encapsulating resin particles VII At the ends of the VII, maleimide is introduced using NHS-PEG (polyethylene glycol) -maleimide reagent, and thiolated anti-HER2 antibody is bound thereto, and anti-HER2 antibody-bound aminocoumarin compound-encapsulating resin particles Was made.
In the same manner as described above, maleimide was introduced at the end of the dye-encapsulated particle iii, and a thiolated anti-Ki67 antibody was bound thereto to produce an anti-Ki67 antibody-bound dye-encapsulated particle.

（組織標本の免疫染色）
　下記工程（１）～（１３）によりヒト乳房組織標本の免疫染色（ＩＨＣ法）を行った。
　工程（１）：キシレンを入れた容器に組織標本を１５分浸漬させた。途中２回キシレンを交換した。
　工程（２）：エタノールを入れた容器に組織標本を１０分浸漬させた。途中２回エタノールを交換した。
　工程（３）：水を入れた容器に組織標本を１０分浸漬させた。
　工程（４）：１０ｍＭクエン酸緩衝液（ｐＨ６．０）に組織標本を浸漬させた。
　工程（５）：１２１℃で５分間オートクレーブ処理を行った。
　工程（６）：ＰＢＳを入れた容器に、オートクレーブ処理後の組織標本を１５分浸漬させた。途中３回ＰＢＳを交換した。
　工程（７）：１％ＢＳＡ含有ＰＢＳを組織標本に載せて、１時間放置した。
　工程（８）：１％ＢＳＡ含有ＰＢＳで０．１ｎＭに調整した抗ＨＥＲ２抗体結合アミノクマリン化合物内包樹脂粒子を組織標本に載せて一晩放置し、ＨＥＲ２を標識した。
　工程（９）：ＰＢＳを入れた容器に標識後の組織標本を１５分浸漬させた。
　工程（１０）：１％ＢＳＡ含有ＰＢＳで０．１ｎＭに調整した抗Ｋｉ６７抗体結合色素内包粒子を、組織標本に載せて一晩放置し、Ｋｉ６７を標識した。
　工程（１１）：ＰＢＳを入れた容器に標識後の組織標本を３０分浸漬させた。
　工程（１２）：組織標本を４％中性パラホルムアルデヒド溶液で１０分間固定処理した後、ＨＥ染色を行った。
　工程（１３）：Merck社製Aquatexを滴下後、カバーガラスを載せ、組織標本を封入した。 (Immunostaining of tissue specimen)
The human breast tissue specimen was immunostained (IHC method) by the following steps (1) to (13).
Step (1): The tissue specimen was immersed in a container containing xylene for 15 minutes. The xylene was changed twice during the process.
Step (2): The tissue specimen was immersed in a container containing ethanol for 10 minutes. The ethanol was changed twice during the process.
Step (3): The tissue specimen was immersed in a container containing water for 10 minutes.
Step (4): The tissue specimen was immersed in a 10 mM citrate buffer (pH 6.0).
Process (5): The autoclave process was performed for 5 minutes at 121 degreeC.
Step (6): The tissue specimen after the autoclave treatment was immersed in a container containing PBS for 15 minutes. The PBS was changed three times during the process.
Step (7): PBS containing 1% BSA was placed on the tissue specimen and allowed to stand for 1 hour.
Step (8): Anti-HER2 antibody-bound aminocoumarin compound-containing resin particles adjusted to 0.1 nM with PBS containing 1% BSA were placed on a tissue specimen and allowed to stand overnight to label HER2.
Step (9): The labeled tissue specimen was immersed in a container containing PBS for 15 minutes.
Step (10): Anti-Ki67 antibody-binding dye-encapsulated particles adjusted to 0.1 nM with PBS containing 1% BSA were placed on a tissue specimen and allowed to stand overnight to label Ki67.
Step (11): The labeled tissue specimen was immersed in a container containing PBS for 30 minutes.
Step (12): The tissue specimen was fixed with a 4% neutral paraformaldehyde solution for 10 minutes, and then stained with HE.
Step (13): After dropping Aquack made by Merck, a cover glass was placed and a tissue specimen was enclosed.

（顕微鏡観察）
　蛍光顕微鏡としてCarl Zeiss社製蛍光顕微鏡を、フィルターセットとしてSemrock製フィルターセットを使用した。フィルターセットは免疫染色剤（緑色用および赤色用）に対応する下記２種類を使用した。 (Microscopic observation)
A fluorescence microscope manufactured by Carl Zeiss was used as the fluorescence microscope, and a filter set manufactured by Semrock was used as the filter set. The following two filter sets corresponding to immunostaining agents (green and red) were used.

Figure JPOXMLDOC01-appb-T000016
Figure JPOXMLDOC01-appb-T000016

　免疫染色後の組織標本をステージに設置し、緑色用および赤色用の２種類のフィルターセットを切り替えながら、フィルターセットを切り替えるごとに、組織標本の蛍光像の蛍光輝点数を計測した。結果を表３に示す。 The tissue specimen after immunostaining was placed on the stage, and each time the filter set was switched while switching between two types of filter sets for green and red, the number of fluorescent luminescent spots in the fluorescence image of the tissue specimen was measured. The results are shown in Table 3.

［実施例１１、１２］
　実施例１１および１２においては、アミノクマリン化合物内包樹脂粒子ＶＩＩの代わりにアミノクマリン化合物内包粒子ＩＸおよびアミノクマリン化合物内包粒子ＶＩＩＩをそれぞれ使用したこと以外は実施例１０と同様の方法により多重免疫染色を行った。結果を表３に示す。 [Examples 11 and 12]
In Examples 11 and 12, multiple immunostaining was performed in the same manner as in Example 10 except that aminocoumarin compound-encapsulated particles IX and aminocoumarin compound-encapsulated particles VIII were used instead of aminocoumarin compound-encapsulated resin particles VII, respectively. went. The results are shown in Table 3.

［比較例３］
　アミノクマリン化合物内包樹脂粒子ＶＩＩの代わりに色素内包粒子ｉｉを使用したこと以外は実施例１０と同様の方法により多重免疫染色を行った。結果を表３に示す。 [Comparative Example 3]
Multiple immunostaining was performed in the same manner as in Example 10 except that the dye-encapsulated particles ii were used instead of the aminocoumarin compound-encapsulated resin particles VII. The results are shown in Table 3.

Figure JPOXMLDOC01-appb-T000017
Figure JPOXMLDOC01-appb-T000017

　表３より、ＨＥＲ２およびＫｉ６７の二重染色の結果、式（１）または（２）で示される構造を有するアミノクマリン化合物Ｉ～ＩＩＩを内包したアミノクマリン化合物内包粒子を用いて免疫染色を行うと、式（１）または（２）で示される構造を有するアミノクマリン化合物以外の色素であるＰｙｒｒｏｍｅｔｈｅｎｅ５５６を内包した色素内包粒子を用いた場合に比較して、緑色輝点の赤色輝点への漏れ込みが少ないことが確認された。 From Table 3, as a result of double staining of HER2 and Ki67, immunostaining was performed using aminocoumarin compound-encapsulated particles encapsulating aminocoumarin compounds I to III having the structure represented by formula (1) or (2). Compared with the case of using dye-containing particles containing Pyrromethene 556, which is a dye other than the aminocoumarin compound having the structure represented by formula (1) or (2), the green bright spot leaks into the red bright spot It was confirmed that there were few.

　さらに、式（１）または（２）で示される構造を有するアミノクマリン化合物Ｉ～ＩＩＩを内包したアミノクマリン化合物内包粒子を用いて免疫染色を行った場合、二重染色の赤輝点数への影響はほとんどないことが表３から確認された。 Furthermore, when immunostaining is performed using aminocoumarin compound-encapsulated particles encapsulating aminocoumarin compounds I to III having the structure represented by formula (1) or (2), the effect of double staining on the number of red bright spots It was confirmed from Table 3 that there is almost no.

［実施例１３］
　下記の方法により緑色および赤色の多重免疫染色を行った。
（色素内包粒子の修飾）
　アミノクマリン化合物内包粒子ＶＩＩＩの末端にＮＨＳ－ＰＥＧ（polyethylene glycol）－マレイミド試薬を用いてマレイミドを導入し、これにチオール化した抗ＣＴＬＡ４抗体を結合させ、抗ＣＴＬＡ４抗体結合アミノクマリン化合物内包粒子を作製した。
　上記と同様に、色素内包粒子ｉｉｉの末端にマレイミドを導入し、これにチオール化した抗ＰＤＬ１抗体を結合させ、抗ＣＴＬＡ４抗体結合色素内包粒子を作製した。 [Example 13]
Multiple immunostaining of green and red was performed by the following method.
(Modification of dye-containing particles)
Aminocoumarin compound-encapsulated particle VIII is introduced with maleimide using NHS-PEG (polyethylene glycol) -maleimide reagent at the end, and thiolated anti-CTLA4 antibody is bound thereto to produce an anti-CTLA4 antibody-bound aminocoumarin compound-encapsulated particle did.
In the same manner as described above, maleimide was introduced into the end of the dye-encapsulated particle iii, and a thiolated anti-PDL1 antibody was bound thereto to produce an anti-CTLA4 antibody-bound dye-encapsulated particle.

（組織標本の免疫染色）
　下記工程（１）～（１３）によりヒト乳房組織標本の免疫染色（ＩＨＣ法）を行った。
　工程（１）：キシレンを入れた容器に組織標本を１５分浸漬させた。途中２回キシレンを交換した。
　工程（２）：エタノールを入れた容器に組織標本を１０分浸漬させた。途中２回エタノールを交換した。
　工程（３）：水を入れた容器に組織標本を１０分浸漬させた。
　工程（４）：１０ｍＭクエン酸緩衝液（ｐＨ６．０）に組織標本を浸漬させた。
　工程（５）：１２１℃で５分間オートクレーブ処理を行った。
　工程（６）：ＰＢＳを入れた容器に、オートクレーブ処理後の組織標本を１５分浸漬させた。途中３回ＰＢＳを交換した。
　工程（７）：１％ＢＳＡ含有ＰＢＳを組織標本に載せて、１時間放置した。
　工程（８）：１％ＢＳＡ含有ＰＢＳで０．１ｎＭに調整した抗ＣＴＬＡ４抗体結合アミノクマリン化合物内包粒子を組織標本に載せて一晩放置し、ＣＴＬＡ４を標識した。
　工程（９）：ＰＢＳを入れた容器に標識後の組織標本を１５分浸漬させた。
　工程（１０）：１％ＢＳＡ含有ＰＢＳで０．１ｎＭに調整した抗ＣＴＬＡ４抗体結合色素内包粒子を、組織標本に載せて一晩放置し、ＰＤＬ１を標識した。
　工程（１１）：ＰＢＳを入れた容器に標識後の組織標本を３０分浸漬させた。
　工程（１２）：組織標本を４％中性パラホルムアルデヒド溶液で１０分間固定処理した後、ＨＥ染色を行った。
　工程（１３）：Merck社製Aquatexを滴下後、カバーガラスを載せ、組織標本を封入した。
（顕微鏡観察）
　実施例１０と同様の方法で顕微鏡観察を行った。結果を表４に示す。 (Immunostaining of tissue specimen)
The human breast tissue specimen was immunostained (IHC method) by the following steps (1) to (13).
Step (1): The tissue specimen was immersed in a container containing xylene for 15 minutes. The xylene was changed twice during the process.
Step (2): The tissue specimen was immersed in a container containing ethanol for 10 minutes. The ethanol was changed twice during the process.
Step (3): The tissue specimen was immersed in a container containing water for 10 minutes.
Step (4): The tissue specimen was immersed in a 10 mM citrate buffer (pH 6.0).
Process (5): The autoclave process was performed for 5 minutes at 121 degreeC.
Step (6): The tissue specimen after the autoclave treatment was immersed in a container containing PBS for 15 minutes. The PBS was changed three times during the process.
Step (7): PBS containing 1% BSA was placed on the tissue specimen and allowed to stand for 1 hour.
Step (8): Anti-CTLA4 antibody-bound aminocoumarin compound-encapsulated particles adjusted to 0.1 nM with PBS containing 1% BSA were placed on a tissue specimen and allowed to stand overnight to label CTLA4.
Step (9): The labeled tissue specimen was immersed in a container containing PBS for 15 minutes.
Step (10): Anti-CTLA4 antibody-binding dye-encapsulated particles adjusted to 0.1 nM with PBS containing 1% BSA were placed on a tissue specimen and allowed to stand overnight to label PDL1.
Step (11): The labeled tissue specimen was immersed in a container containing PBS for 30 minutes.
Step (12): The tissue specimen was fixed with a 4% neutral paraformaldehyde solution for 10 minutes, and then stained with HE.
Step (13): After dropping Aquack made by Merck, a cover glass was placed and a tissue specimen was enclosed.
(Microscopic observation)
Microscopic observation was performed in the same manner as in Example 10. The results are shown in Table 4.

［実施例１４］
　下記の方法により緑色および赤色の多重免疫染色を行った。
（色素内包粒子の修飾）
　アミノクマリン化合物内包粒子ＶＩＩＩの末端にＮＨＳ－ＰＥＧ（polyethylene glycol）－マレイミド試薬を用いてマレイミドを導入し、これにチオール化した抗ＣＤ８抗体（Dako社製「抗CD8マウスモノクロナール抗体(C8/144B)」）を結合させ、抗ＣＤ８抗体結合アミノクマリン化合物内包粒子を作製した。
　上記と同様に、色素内包粒子ｉｉｉの末端にマレイミドを導入し、これにチオール化した抗ＰＤＬ１抗体を結合させ、抗ＰＤＬ１抗体結合色素内包粒子を作製した。 [Example 14]
Multiple immunostaining of green and red was performed by the following method.
(Modification of dye-containing particles)
Maleimide was introduced into the end of the aminocoumarin compound-encapsulated particles VIII using NHS-PEG (polyethylene glycol) -maleimide reagent, and thiolated anti-CD8 antibody ("DCD" anti-CD8 mouse monoclonal antibody (C8 / 144B )]) Was bound to produce anti-CD8 antibody-bound aminocoumarin compound-encapsulated particles.
In the same manner as described above, maleimide was introduced into the end of the dye-encapsulated particle iii, and a thiolated anti-PDL1 antibody was bound thereto to produce an anti-PDL1 antibody-bound dye-encapsulated particle.

（組織標本の免疫染色）
　下記工程（１）～（１３）によりヒト乳房組織標本の免疫染色（ＩＨＣ法）を行った。
　工程（１）：キシレンを入れた容器に組織標本を１５分浸漬させた。途中２回キシレンを交換した。
　工程（２）：エタノールを入れた容器に組織標本を１０分浸漬させた。途中２回エタノールを交換した。
　工程（３）：水を入れた容器に組織標本を１０分浸漬させた。
　工程（４）：１０ｍＭクエン酸緩衝液（ｐＨ６．０）に組織標本を浸漬させた。
　工程（５）：１２１℃で５分間オートクレーブ処理を行った。
　工程（６）：ＰＢＳを入れた容器に、オートクレーブ処理後の組織標本を１５分浸漬させた。途中３回ＰＢＳを交換した。
　工程（７）：１％ＢＳＡ含有ＰＢＳを組織標本に載せて、１時間放置した。
　工程（８）：１％ＢＳＡ含有ＰＢＳで０．１ｎＭに調整した抗ＣＤ８抗体結合アミノクマリン化合物内包粒子を組織標本に載せて一晩放置し、ＣＤ８を標識した。
　工程（９）：ＰＢＳを入れた容器に標識後の組織標本を１５分浸漬させた。
　工程（１０）：１％ＢＳＡ含有ＰＢＳで０．１ｎＭに調整した抗ＰＤＬ１抗体結合色素内包粒子を組織標本に載せて一晩放置し、ＰＤＬ１を標識した。
　工程（１１）：ＰＢＳを入れた容器に標識後の組織標本を３０分浸漬させた。
　工程（１２）：組織標本を４％中性パラホルムアルデヒド溶液で１０分間固定処理した後、ＨＥ染色を行った。
　工程（１３）：Merck社製Aquatexを滴下後、カバーガラスを載せ、組織標本を封入した。
（顕微鏡観察）
　実施例１０と同様の方法で顕微鏡観察を行った。結果を表４に示す。 (Immunostaining of tissue specimen)
The human breast tissue specimen was immunostained (IHC method) by the following steps (1) to (13).
Step (1): The tissue specimen was immersed in a container containing xylene for 15 minutes. The xylene was changed twice during the process.
Step (2): The tissue specimen was immersed in a container containing ethanol for 10 minutes. The ethanol was changed twice during the process.
Step (3): The tissue specimen was immersed in a container containing water for 10 minutes.
Step (4): The tissue specimen was immersed in a 10 mM citrate buffer (pH 6.0).
Process (5): The autoclave process was performed for 5 minutes at 121 degreeC.
Step (6): The tissue specimen after the autoclave treatment was immersed in a container containing PBS for 15 minutes. The PBS was changed three times during the process.
Step (7): PBS containing 1% BSA was placed on the tissue specimen and allowed to stand for 1 hour.
Step (8): Anti-CD8 antibody-bound aminocoumarin compound-encapsulated particles adjusted to 0.1 nM with PBS containing 1% BSA were placed on a tissue specimen and allowed to stand overnight to label CD8.
Step (9): The labeled tissue specimen was immersed in a container containing PBS for 15 minutes.
Step (10): Anti-PDL1 antibody-binding dye-encapsulated particles adjusted to 0.1 nM with PBS containing 1% BSA were placed on a tissue specimen and allowed to stand overnight to label PDL1.
Step (11): The labeled tissue specimen was immersed in a container containing PBS for 30 minutes.
Step (12): The tissue specimen was fixed with a 4% neutral paraformaldehyde solution for 10 minutes, and then stained with HE.
Step (13): After dropping Aquack made by Merck, a cover glass was placed and a tissue specimen was enclosed.
(Microscopic observation)
Microscopic observation was performed in the same manner as in Example 10. The results are shown in Table 4.

［実施例１５］
　下記の方法により緑色および赤色の多重免疫染色を行った。
（色素内包粒子の修飾）
　アミノクマリン化合物内包粒子ＶＩＩＩの末端にＮＨＳ－ＰＥＧ（polyethylene glycol）－マレイミド試薬を用いてマレイミドを導入し、これにチオール化した抗ＣＤ３０抗体（Dako社製「抗CD30マウスモノクロナール抗体(BerH2)）を結合させ、抗ＣＤ３０抗体結合アミノクマリン化合物内包粒子を作製した。
　上記と同様に、色素内包粒子ｉｉｉの末端にマレイミドを導入し、これにチオール化した抗ＰＤＬ１抗体を結合させ、抗ＰＤＬ１抗体結合色素内包粒子を作製した。 [Example 15]
Multiple immunostaining of green and red was performed by the following method.
(Modification of dye-containing particles)
Anti-CD30 antibody (manufactured by Dako, “Anti-CD30 mouse monoclonal antibody (BerH2)) obtained by introducing maleimide into the end of aminocoumarin compound-encapsulated particles VIII using NHS-PEG (polyethylene glycol) -maleimide reagent and thiolating it. Were bound to produce anti-CD30 antibody-bound aminocoumarin compound-encapsulated particles.
In the same manner as described above, maleimide was introduced at the end of the dye-encapsulated particle iii, and a thiolated anti-PDL1 antibody was bound thereto to produce an anti-PDL1 antibody-bound dye-encapsulated particle.

（組織標本の免疫染色）
　下記工程（１）～（１３）によりヒト乳房組織標本の免疫染色（ＩＨＣ法）を行った。
　工程（１）：キシレンを入れた容器に組織標本を１５分浸漬させた。途中２回キシレンを交換した。
　工程（２）：エタノールを入れた容器に組織標本を１０分浸漬させた。途中２回エタノールを交換した。
　工程（３）：水を入れた容器に組織標本を１０分浸漬させた。
　工程（４）：１０ｍＭクエン酸緩衝液（ｐＨ６．０）に組織標本を浸漬させた。
　工程（５）：１２１℃で５分間オートクレーブ処理を行った。
　工程（６）：ＰＢＳを入れた容器に、オートクレーブ処理後の組織標本を１５分浸漬させた。途中３回ＰＢＳを交換した。
　工程（７）：１％ＢＳＡ含有ＰＢＳを組織標本に載せて、１時間放置した。
　工程（８）：１％ＢＳＡ含有ＰＢＳで０．１ｎＭに調整した抗ＣＤ３０抗体結合アミノクマリン化合物内包粒子を組織標本に載せて一晩放置し、ＣＤ３０を標識した。
　工程（９）：ＰＢＳを入れた容器に標識後の組織標本を１５分浸漬させた。
　工程（１０）：１％ＢＳＡ含有ＰＢＳで０．１ｎＭに調整した抗ＰＤＬ１抗体結合色素内包粒子を組織標本に載せて一晩放置し、ＰＤＬ１を標識した。
　工程（１１）：ＰＢＳを入れた容器に標識後の組織標本を３０分浸漬させた。
　工程（１２）：組織標本を４％中性パラホルムアルデヒド溶液で１０分間固定処理した後、ＨＥ染色を行った。
　工程（１３）：Merck社製Aquatexを滴下後、カバーガラスを載せ、組織標本を封入した。
（顕微鏡観察）
　実施例１０と同様の方法で顕微鏡観察を行った。結果を表４に示す。 (Immunostaining of tissue specimen)
The human breast tissue specimen was immunostained (IHC method) by the following steps (1) to (13).
Step (1): The tissue specimen was immersed in a container containing xylene for 15 minutes. The xylene was changed twice during the process.
Step (2): The tissue specimen was immersed in a container containing ethanol for 10 minutes. The ethanol was changed twice during the process.
Step (3): The tissue specimen was immersed in a container containing water for 10 minutes.
Step (4): The tissue specimen was immersed in a 10 mM citrate buffer (pH 6.0).
Process (5): The autoclave process was performed for 5 minutes at 121 degreeC.
Step (6): The tissue specimen after the autoclave treatment was immersed in a container containing PBS for 15 minutes. The PBS was changed three times during the process.
Step (7): PBS containing 1% BSA was placed on the tissue specimen and allowed to stand for 1 hour.
Step (8): Anti-CD30 antibody-bound aminocoumarin compound-encapsulated particles adjusted to 0.1 nM with PBS containing 1% BSA were placed on a tissue specimen and allowed to stand overnight to label CD30.
Step (9): The labeled tissue specimen was immersed in a container containing PBS for 15 minutes.
Step (10): Anti-PDL1 antibody-binding dye-encapsulated particles adjusted to 0.1 nM with PBS containing 1% BSA were placed on a tissue specimen and allowed to stand overnight to label PDL1.
Step (11): The labeled tissue specimen was immersed in a container containing PBS for 30 minutes.
Step (12): The tissue specimen was fixed with a 4% neutral paraformaldehyde solution for 10 minutes, and then stained with HE.
Step (13): After dropping Aquack made by Merck, a cover glass was placed and a tissue specimen was enclosed.
(Microscopic observation)
Microscopic observation was performed in the same manner as in Example 10. The results are shown in Table 4.

［比較例４］
　アミノクマリン化合物内包粒子ＶＩＩＩの代わりに色素内包粒子ｉｉを使用したこと以外は実施例１３と同様の方法により緑色および赤色の多重免疫染色を行った。結果を表４に示す。 [Comparative Example 4]
Multiple immunostaining of green and red was performed in the same manner as in Example 13 except that the dye-encapsulated particles ii were used instead of the aminocoumarin compound-encapsulated particles VIII. The results are shown in Table 4.

［比較例５］
　アミノクマリン化合物内包粒子ＶＩＩＩの代わりに色素内包粒子ｉｉを使用したこと以外は実施例１４と同様の方法により緑色および赤色の多重免疫染色を行った。結果を表４に示す。 [Comparative Example 5]
Green and red multiple immunostaining was performed in the same manner as in Example 14 except that the dye-encapsulated particles ii were used instead of the aminocoumarin compound-encapsulated particles VIII. The results are shown in Table 4.

［比較例６］
　アミノクマリン化合物内包粒子ＶＩＩＩの代わりに色素内包粒子ｉｉを使用したこと以外は実施例１５と同様の方法により緑色および赤色の多重免疫染色を行った。結果を表４に示す。 [Comparative Example 6]
Green and red multiple immunostaining was performed in the same manner as in Example 15 except that the dye-encapsulated particles ii were used instead of the aminocoumarin compound-encapsulated particles VIII. The results are shown in Table 4.

Figure JPOXMLDOC01-appb-T000018
Figure JPOXMLDOC01-appb-T000018

　表４より、ＰＤＬ１とＣＴＬＡ４、ＣＤ８またはＣＤ３０との二重染色の結果、式（２）で示される構造を有するアミノクマリン化合物ＩＩを内包したアミノクマリン化合物内包粒子を用いて免疫染色を行うと、式（１）または（２）で示される構造を有するアミノクマリン化合物以外の色素であるＰｙｒｒｏｍｅｔｈｅｎｅ５５６を内包した色素内包粒子を用いた場合に比較して、緑色輝点の赤色輝点への漏れ込みが少ないことが確認された。 From Table 4, as a result of double staining with PDL1 and CTLA4, CD8 or CD30, immunostaining was performed using aminocoumarin compound-encapsulated particles encapsulating aminocoumarin compound II having the structure represented by formula (2). Compared to the case of using dye-containing particles containing Pyrromethene 556, which is a dye other than the aminocoumarin compound having the structure represented by formula (1) or (2), the green bright spot leaks into the red bright spot. It was confirmed that there were few.

　さらに、式（２）で示される構造を有するアミノクマリン化合物ＩＩを内包したアミノクマリン化合物内包粒子を用いて免疫染色を行った場合、ＨＥＲ２およびＫｉ６７の二重染色の場合と同様に、二重染色の赤輝点数への影響はほとんどないことが表４から確認された。 Further, when immunostaining is performed using aminocoumarin compound-encapsulated particles encapsulating aminocoumarin compound II having the structure represented by formula (2), double staining is performed as in the case of double staining of HER2 and Ki67. Table 4 confirmed that there was almost no effect on the number of red bright spots.

Claims (5)

　下記式（１）または（２）で示される構造を有するアミノクマリン化合物またはその塩を母体粒子に内包してなるアミノクマリン化合物内包粒子を用いて標識を行う蛍光標識法。
Figure JPOXMLDOC01-appb-C000001
 （式（１）中、Ｒは、それぞれ独立に水素原子またはメチル基を表わし、Ｑはイオウ原子、酸素原子またはＮ－Ｒ1を表わし、Ｒ1は水素原子またはメチル基を表わす。）
Figure JPOXMLDOC01-appb-C000002
 （式（２）中、Ａは、それぞれ独立に水素原子またはメチル基を表わし、Ｑはイオウ原子、酸素原子またはＮ－Ｒ1を表わし、Ｒ1は水素原子またはメチル基を表わす。） A fluorescent labeling method in which labeling is performed using aminocoumarin compound-encapsulated particles in which an aminocoumarin compound having a structure represented by the following formula (1) or (2) or a salt thereof is encapsulated in base particles.
Figure JPOXMLDOC01-appb-C000001
 (In formula (1), each R independently represents a hydrogen atom or a methyl group, Q represents a sulfur atom, an oxygen atom or N—R 1 , and R 1 represents a hydrogen atom or a methyl group.)
Figure JPOXMLDOC01-appb-C000002
 (In the formula (2), A independently represents a hydrogen atom or a methyl group, Q represents a sulfur atom, an oxygen atom or N—R 1 , and R 1 represents a hydrogen atom or a methyl group.) 　前記アミノクマリン化合物内包粒子の平均粒径が８０～２００ｎｍである請求項１に記載の蛍光標識法。 The fluorescent labeling method according to claim 1, wherein the aminocoumarin compound-encapsulated particles have an average particle size of 80 to 200 nm. 　前記アミノクマリン化合物内包粒子を用いた標識を含む多重標識を行う請求項１または２に記載の蛍光標識法。 The fluorescent labeling method according to claim 1 or 2, wherein multiple labeling including labeling using the aminocoumarin compound-encapsulated particles is performed. 　免疫染色法またはＦＩＳＨである請求項１～３のいずれかに記載の蛍光標識法。 The fluorescent labeling method according to any one of claims 1 to 3, which is an immunostaining method or FISH. 　前記免疫染色法は、ＰＤＬ１、ＣＴＬＡ４、ＣＤ８、ＣＤ３０、ＣＤ４８、ＣＤ５９、ＩＤＯ、 ＴＤＯ、ＣＳＦ－１Ｒ、ＨＤＡＣ、ＣＸＣＲ４、ＦＬＴ－３、ＴＩＧＩＴ、ＩＮＦ-α、INF-β、INF-ω、INF-ε、INF-κ、INF-γ、INF-λ ＣＳＦ、ＥＰＯ、ＥＧＦ、ＦＧＦ、ＰＤＧＦ、ＨＧＦ、ＴＧＦ、ＣＤ３、ＣＤ４、ＣＤ２５、ＣＤ２８、ＣＤ８０、ＣＤ８６、ＣＤ１６０、ＣＤ５７、ＯＸ４０、ＯＸ４０Ｌ、ＩＣＯＳ、ＩＣＯＳＬ、ＣＤ１５５、ＣＤ２２６、ＣＤ１１２、ＣＤ２７、ＣＤ７０、４－１ＢＢ、４－１ＢＢＬ、ＧＩＴＲ、ＧＩＴＲＬ、ＢＴＬＡ、ＨＶＥＭ、ＴＩＭ－３、Ｇａｌｅｃｔｉｎ－９、ＬＡＧ－３、Ｂ７－Ｈ３、Ｂ７－Ｈ４、Ｂ７－Ｈ５、ＣＤ４０、ＣＤ４０Ｌ、ＰＤ－１、ＰＤ－Ｌ２、２Ｂ４、ＫＬＲＧ－１、Ｅ－Ｃａｄｈｅｒｉｎ、Ｎ－Ｃａｄｈｅｒｉｎ、Ｒ－Ｃａｄｈｅｒｉｎ、ＣＤ６８、ＣＤ１６３およびＣＳＦ１－Ｒから選択される少なくとも２つの染色対象タンパク質に対してそれぞれ異なる色素を用いて多重染色を行い、前記染色対象タンパク質の少なくとも１つを、前記アミノクマリン化合物内包粒子を用いて染色する請求項４に記載の蛍光標識法。 The immunostaining method includes PDL1, CTLA4, CD8, CD30, CD48, CD59, IDO, TDO, CSF-1R, HDAC, CXCR4, FLT-3, TIGIT, INF-α, INF-β, INF-ω, INF- ε, INF-κ, INF-γ, INF-λ CSF, EPO, EGF, FGF, PDGF, HGF, TGF, CD3, CD4, CD25, CD28, CD80, CD86, CD160, CD57, OX40, OX40L, ICOS, ICOSL , CD155, CD226, CD112, CD27, CD70, 4-1BB, 4-1BBL, GITR, GITRL, BTLA, HVEM, TIM-3, Galectin-9, LAG-3, B7-H3, B7-H4, B7-H5 CD40, CD40L, PD-1, PD-L2, 2B4, KLRG-1, E-Cadh erin, N-cadherin, R-cadherin, CD68, CD163 and CSF1-R are subjected to multiple staining using different dyes, and at least one of the proteins to be stained is selected. The fluorescent labeling method according to claim 4, wherein the aminocoumarin compound-encapsulated particles are used for staining.
PCT/JP2018/004802 2017-02-14 2018-02-13 Fluorescent labeling method Ceased WO2018151071A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2018568515A JP7095603B2 (en) 2017-02-14 2018-02-13 Fluorescent labeling method

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2017-024875 2017-02-14
JP2017024875 2017-02-14

Publications (1)

Publication Number Publication Date
WO2018151071A1 true WO2018151071A1 (en) 2018-08-23

Family

ID=63170319

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2018/004802 Ceased WO2018151071A1 (en) 2017-02-14 2018-02-13 Fluorescent labeling method

Country Status (2)

Country Link
JP (1) JP7095603B2 (en)
WO (1) WO2018151071A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019172968A (en) * 2018-03-28 2019-10-10 日本化薬株式会社 Coumarin compound, and pigment composition containing the same

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH069892A (en) * 1992-06-22 1994-01-18 Nippon Kanko Shikiso Kenkyusho:Kk Coumarin derivative
JPH06271599A (en) * 1993-01-29 1994-09-27 Bayer Ag Sulfocoumarin-containing nucleotides and their use in detection of nucleic acid
JPH07508309A (en) * 1992-05-13 1995-09-14 モレキュラー・プロウブズ・インコーポレーテッド Fluorescent microparticles with controllable enhanced Stokes shift
JP2004309458A (en) * 2003-03-27 2004-11-04 Institute Of Physical & Chemical Research Time-resolved fluorescence microscope
JP2006045314A (en) * 2004-08-03 2006-02-16 Fuji Electric Holdings Co Ltd Salt made of fluorescent anion and fluorescent cation and color conversion film using the same
WO2015045961A1 (en) * 2013-09-26 2015-04-02 コニカミノルタ株式会社 Fluorescent nanoparticle label, multiple immunostain kit, and multiple immunostaining method
JP2015093878A (en) * 2013-11-08 2015-05-18 コニカミノルタ株式会社 Fluorescent dye-containing resin particles, fluorescent dye-containing resin particle set for tissue multiple staining containing the fluorescent dye-containing resin particles, and tissue multiple staining method using the fluorescent dye-containing resin particles
WO2016129444A1 (en) * 2015-02-12 2016-08-18 コニカミノルタ株式会社 Antibody-conjugated integrated phosphor nanoparticles, method for manufacturing antibody-conjugated integrated phosphor nanoparticles, and immunostaining kit

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103360377B (en) * 2012-03-29 2017-09-19 住友化学株式会社 dye compound
WO2014192972A1 (en) * 2013-05-30 2014-12-04 Canon Kabushiki Kaisha Macrophage identification agent, and identification method, sorting method, evaluation method, screening method and kit using the macrophage identifier agent

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07508309A (en) * 1992-05-13 1995-09-14 モレキュラー・プロウブズ・インコーポレーテッド Fluorescent microparticles with controllable enhanced Stokes shift
JPH069892A (en) * 1992-06-22 1994-01-18 Nippon Kanko Shikiso Kenkyusho:Kk Coumarin derivative
JPH06271599A (en) * 1993-01-29 1994-09-27 Bayer Ag Sulfocoumarin-containing nucleotides and their use in detection of nucleic acid
JP2004309458A (en) * 2003-03-27 2004-11-04 Institute Of Physical & Chemical Research Time-resolved fluorescence microscope
JP2006045314A (en) * 2004-08-03 2006-02-16 Fuji Electric Holdings Co Ltd Salt made of fluorescent anion and fluorescent cation and color conversion film using the same
WO2015045961A1 (en) * 2013-09-26 2015-04-02 コニカミノルタ株式会社 Fluorescent nanoparticle label, multiple immunostain kit, and multiple immunostaining method
JP2015093878A (en) * 2013-11-08 2015-05-18 コニカミノルタ株式会社 Fluorescent dye-containing resin particles, fluorescent dye-containing resin particle set for tissue multiple staining containing the fluorescent dye-containing resin particles, and tissue multiple staining method using the fluorescent dye-containing resin particles
WO2016129444A1 (en) * 2015-02-12 2016-08-18 コニカミノルタ株式会社 Antibody-conjugated integrated phosphor nanoparticles, method for manufacturing antibody-conjugated integrated phosphor nanoparticles, and immunostaining kit

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019172968A (en) * 2018-03-28 2019-10-10 日本化薬株式会社 Coumarin compound, and pigment composition containing the same
JP7261609B2 (en) 2018-03-28 2023-04-20 日本化薬株式会社 Coumarin compound and pigment composition containing the same

Also Published As

Publication number Publication date
JP7095603B2 (en) 2022-07-05
JPWO2018151071A1 (en) 2019-12-12

Similar Documents

Publication Publication Date Title
US10551386B2 (en) Biological substance detection method
JP7147724B2 (en) Staining agent for tissue staining, method for producing staining agent for tissue staining, and tissue staining kit containing staining agent for tissue staining
US10458983B2 (en) Method for detecting biological material
CN108473505B (en) Polyfluoreno [4,5-cde ] oxepine conjugates and their use in analyte detection methods
WO2018151071A1 (en) Fluorescent labeling method
JP7151489B2 (en) Aminocoumarin compound and aminocoumarin compound-encapsulating resin particles
US20250283800A1 (en) Probes for fluorescence imaging
JP6187170B2 (en) Fluorescent dye-containing resin particles, fluorescent dye-containing resin particle set for tissue multiple staining containing the fluorescent dye-containing resin particles, and tissue multiple staining method using the fluorescent dye-containing resin particles
WO2018150450A1 (en) Aminocoumarin compound, and aminocoumarin compound-containing resin particles
JP6447679B2 (en) Fluorescent dye-containing resin particles and fluorescent dye-containing resin particle set for tissue multiple staining containing the fluorescent dye-containing resin particles
KR102066344B1 (en) Novel fluorescent compound for labelling nucleic acids and the preparation method thereof
WO2021230134A1 (en) Image formation method
Subach et al. Next-generation orange-to-far-red photoconvertible fluorescent protein for single-molecule microscopy and protein dynamic tracking
DIAZ et al. Aminoacridine dyes and the secondary structure of DNA in situ
EP4540263A2 (en) Bicyclononyne reagents for cell imaging

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18754494

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2018568515

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 18754494

Country of ref document: EP

Kind code of ref document: A1